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1. Abstract 
We present a bibliometric analysis of recently published full economic evaluations of health interventions 
and reflect critically on the implications of our findings for this growing field.  We created a database 
drawing on 14 health, economic, and/or general literature databases for articles published between 1 
January 2012 and 1 May 2014 and identified 2,844 economic evaluations meeting our criteria. We 
present findings regarding the sensitivity, specificity, and added value of searches in the different 
databases. We examine the distribution of publications between countries, regions, and health areas 
studied and compare the relative volume of research with disease burden. We analyze authors’ country 
and institutional affiliations, journals and journal type, language, and type of economic evaluation 
conducted. More than 1,200 economic evaluations were published annually, of which 4% addressed low-
income countries, 4% lower-middle-income countries, 14% upper-middle-income countries, and 83% 
high-income countries. Across country income levels, 53%, 54%, 86%, and 100% of articles, respectively, 
included an author based in a country within the income level studied.  Biomedical journals published 
74% of economic evaluations.  The volume of research across health areas correlates more closely with 
disease burden in high-income than in low- and middle-income countries. Our findings provide an 
empirical basis for further study on methods, research prioritization, and capacity development in health 
economic evaluation. 
 
Key words: Bibliometrics, Economic evaluation, Cost-Effectiveness Analysis, Low- and middle-income 
countries, High-income countries 
 
JEL codes: I10 (Health, General); D610 (Allocative Efficiency; Cost-Benefit Analysis), I120 (Health 
Production) 
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2. Introduction 
“Bibliometrics” is the quantitative analysis of written communication in forms such as journal articles and 
books.(Pritchard, 1969) Bibliometric analyses can examine a body of knowledge far larger than that which 
can be assessed and synthesized in a systematic review and so allow reflection on the past, present, and 
future of entire fields of research.  Wagstaff and Culyer’s 2012 bibliometric analysis of the field of health 
economics, which updated and extended prior work by Rubin and Chang (2003), set out to undertake 
such an analysis of the entirety of health economics. Their ambitious work examined publications across 
42 years (1969-2010) and generated much discussed rankings of the leading authors, institutions, and 
topics of health economics research over time.  By restricting their analyses to journals indexed in Econlit, 
however, they captured very little of the literature in health economic evaluation, an important, and 
growing area of health economics.    
This article presents a bibliometric analysis of recently published, full health economic evaluations 
(Drummond et al., 2005) and reflects critically on the implications of our findings. We stratify our analyses 
by the income group classification (World Bank, 2015) of the countries studied to allow comparisons 
across income groups. This stratification ensures that findings regarding low- and middle-income 
countries (L&MICs) receive due attention, given  their far greater burden of disease, more constrained 
resources, and lesser focus in the methodological literature to date, as well as the fact that they are home 
to 84% of the world’s population (World Health Organization., 2014). In light of the growing interest in 
global health and priority setting, this contribution to the evidence base is also timely. 
A previous bibliometric analysis of cost-effectiveness analyses (CEAs) was limited to studies reporting 
outcomes as cost per quality-adjusted life-year (QALY) up to 2006 (Greenberg et al., 2010). As QALYs 
were only used in a total of 23 L&MIC CEAs up to 2006 (Harker and Guinness, 2015), this restriction 
biased Greenberg and others’ findings towards studies undertaken in HICs and omitted nearly half of full 
economic evaluations (as we will show). Much has also changed since 2006, with a rapid expansion in the 
literature, including in L&MICs.  
By 1984, just a handful of economic evaluations of health interventions had been conducted in L&MICs 
(Mills and Thomas, 1984) and even in 2000, Walker and Fox-Rushby (2000) were still able to review 
critically the 107 economic evaluations of interventions to address communicable diseases in L&MICs 
published between 1984 and 1997. In the past decade, however, the body of work has expanded such 
that it has been possible for reviews to focus on specific disease areas for example, non-communicable 
diseases (Mulligan et al., 2006); road traffic injuries (Waters et al., 2004); malaria (Goodman and Mills, 
1999, White et al., 2011); various aspects of HIV/AIDS (Creese et al., 2002, Galarraga et al., 2009, 
Walensky et al., 2010, Johri and Ako-Arrey, 2011) and tuberculosis (Fitzpatrick and Floyd, 2012, Chavan et 
al., 2011); vaccination for Haemophilus influenzae type b (Griffiths and Miners, 2009), seasonal (Ott et al., 
2013) and pandemic influenza (Perez Velasco et al., 2012); human papilloma virus (Natunen et al., 2013, 
Fesenfeld et al., 2013); cardiovascular diseases (Suhrcke et al., 2012); surgery (Chao et al., 2014); and 
strategies to improve the demand and supply of maternal and neonatal care (Mangham-Jefferies et al., 
2014). Reviews of economic evaluations in L&MICs have also narrowed their focus by geography, for 
example, to Meso-America (Valencia-Mendoza et al., 2011), Latin America and the Caribbean 
(Augustovski et al., 2009), Thailand (Teerawattananon et al., 2007), Nigeria (Gavaza et al., 2010), Tanzania 
(Mori and Robberstad, 2012) and Ghana (Odame, 2013). In adopting a more constrained perspective, 
these reviews have allowed important insights into the economic evidence for specific disease areas or 
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geographies, but have not provided a wider perspective on the overall economic evaluation literature in 
L&MICs, nor been able to compare this literature with the far larger body of economic evaluations in 
high-income countries (HICs).  
In the following sections, we describe the methods for generating and analysing our data, present our 
results, and reflect on the state of the field and the implications of our findings for research priority 
setting and capacity development.   
 
 
3. Methods 
We began by developing a comprehensive database of peer-reviewed research articles reporting a 
primary, full economic evaluation. Following Drummond et al, we defined “full economic evaluation” as 
studies which evaluate the efficiency of alternative interventions or courses of action by combining data 
on the costs and effects on human health of the alternatives in CEA, cost-utility analysis (CUA), or cost-
benefit analysis (CBA). (Drummond et al., 2008) Further, we aimed to restrict our database to articles 
which went beyond simple reporting of some cost and effect data, rather including only articles which 
either (i) produced a summary measure of efficiency, such as a ratio (e.g. incremental cost-effectiveness 
ratio), probability (e.g. that an intervention is cost-effective given a defined threshold), difference (e.g. 
incremental net benefit), and/or graph, such as a cost-effectiveness plane or cost-effectiveness 
acceptability curve as recommended in ISPOR guidelines (Ramsey et al., 2005), or (ii) which demonstrated 
strict dominance (i.e. that one intervention is both more costly and less effective than the other). We 
defined “primary research” to include the production of a novel estimate (i.e. to include modelling 
studies) and to exclude reviews which only cite previously published estimates. Our analysis was 
restricted to articles published from 1 January 2012 to the date of our searches, 3 May 2014, comprising a 
period of 28 months.  
In the following sections we describe the process of constructing the database and our analytical 
methods. 
3.1. Data 
Search strategies 
Appendix 1 illustrates our search strategy in a flow diagram adapted from the PRISMA guidelines for 
systematic reviews.(Liberati et al., 2009) We identified 17 potential databases for our search by 
consulting recent systematic reviews of economic evaluations and a health sciences librarian to identify 
databases which seemed, prima facie, to be potentially useful or used by researchers.  
Based on preliminary searches in all databases and a review of their content and functionality, we 
selected 14 databases for our final search: two health economics databases (the National Health Service 
Economic Evaluations Database (NHS EED) and the Health Economic Evaluations Database (HEED)), one 
economics database (EconLit), one general literature database (Scopus), two broad databases (the 
Science Citation Index Extended (SCI) and the Social Science Citation Index (SSCI), which were searched 
simultaneously), and eight health sciences databases (Embase, Medline including in-process, Latin 
American Health Sciences Literature (LILACS), Global Health, PsycInfo, Scielo, Biosis, and Cinahl). We 
excluded Google Scholar because Google prevents bulk downloading of citations; Pubmed because we 
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were able to obtain the same set of articles (Medline, Medline-in-process, and Pubmed-not-Medline) in 
our search of the Ovid SP interface, which is more user-friendly; and the Tufts Cost-Effectiveness Analysis 
Registry because its coverage was limited to articles published in English which report outcomes as QALYs 
and it charges substantial access fees.  
Search strategies were optimized individually for each database, taking into account the scope of each 
database and the features of its user interface. Careful checks were performed to ensure that the initial 
search was as sensitive as possible, and that any restrictions increased specificity without compromising 
sensitivity. Each time we considered an additional restriction to increase the specificity of the search, 
such as excluding all articles with the word “protocol” in the title, we first reviewed the first one hundred 
excluded records, and revised the search strategy if any excluded records were found to meet our 
inclusion criteria. Full details of the final search strategy employed in each database are provided in 
Appendix 2 and further discussion of the reasons for not using controlled vocabulary indexing terms (e.g. 
MeSH terms) is available in Appendix 3. 
Merging and screening 
Search results were exported to Excel. We identified duplicate records to produce a set of unique records 
linked to the bibliographic data in all of the databases in which they were found. By comparing multiple 
databases and carefully reviewing data, we corrected many of the errors within the bibliographic data. 
Titles and, if necessary, abstracts and in some cases full text, were screened by one author (CP) to 
determine whether they met our inclusion criteria. Although only English-language search terms were 
used, no language restrictions were applied. Keyword searches of all text fields were used to facilitate 
identification of articles for exclusion (using terms such as “review” and “protocol”) and inclusion (using 
terms such as “dominant” and “cost-utility”).   
We excluded articles which described themselves as CEA, CUA, or CBA but did not meet our inclusion 
criteria. For example, self-proclaimed “cost-benefit analyses” which only compared the costs of 
interventions with cost savings resulting from reduced subsequent health care use were excluded as they 
did not measure health benefits. Cost-minimization analyses were similarly excluded (Dakin and 
Wordsworth, 2013), as were the many articles declaring an intervention “cost-effective” which did not 
analyze both costs and effects. 
3.2. Analyses 
All analyses are disaggregated by country income group and were conducted in Microsoft Excel. 
Databases 
For each of the 14 databases, we provide estimates of the sensitivity (% of the total number of unique 
economic evaluations identified), specificity (% of search results for each database classified as economic 
evaluations), and added value (% unique economic evaluations identified by given database and not also 
identified by another database identifying a greater % of economic evaluations) of our search.  
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Geographic areas studied 
Key term searches were developed to classify articles by country (or countries) studied, which were then 
mapped onto World Bank income groups and regions (World Bank, 2015).1 All potentially ambiguous 
names (including Congo, Korea, India, China, Niger, Japan, England, and Guinea) were reviewed, as were 
all articles not classified by any search term or classified as analysing multiple income groups. Articles 
which described themselves as studying a region or set of countries (such as “malaria endemic countries” 
(WHO Global Malaria Programme., 2014)) were classified according to all the countries within that region. 
A single article could be classified as belonging to multiple income levels or regions. 
Health areas  
We developed a classification of 25 health areas so as to allow comparability with the Global Burden of 
Disease (GBD) estimates (World Health Organization., 2014), to be implementable with an electronic key 
term search, and to permit meaningful analysis. In Appendix 4, we show how our 25 health areas map 
onto the GBD and onto the World Health Organization’s international classification of disease, version 10 
(ICD-10) (World Health Organization., 2011). A set of up to 49 search terms was developed for each of our 
health areas through an iterative process. 
As with countries studied, a single article could be classified as belonging to multiple health areas. For 
example, we counted economic evaluations of interventions for gestational diabetes as both “maternal 
and newborn health” and “diabetes”, and interventions to address HIV and tuberculosis co-infection 
(Pawlowski et al., 2012) as addressing each disease.  While this could be considered double-counting, we 
argue that interventions addressing multiple areas do not contribute any less to each area than those 
interventions addressing only one disease. Further information is available in Appendix 5.  
We then compared the distribution of health areas studied in economic evaluations to the GBD. 
Comparisons are presented graphically with scatter plots comparing the volume of economic evaluations 
and burden of disease by a) ranking and b) proportion of total, disaggregated by income group and in 
total, which allows us both to assess the correlation and to identify health areas which are outliers 
meriting deeper exploration. 
Languages and journals 
Journal names were classified as: 1) biomedical, 2) health economics, services, policy, and/or social 
sciences, or 3) other. (Appendix 6) The proportion of health economic evaluations published in each 
journal type were analyzed overall and by income group, as were the top ten journals, and the 
concentration of economic evaluations.  
The language of the full text was also analyzed. Where the full text was available in English and another 
language, the article was categorized as English to permit analysis of what would be missed if only 
English-language publications were considered. As there were many errors in the language data in the 
bibliographic databases, these data were also compared with the journal title and country studied, and in 
some cases the full text or journal website examined, to arrive at a final language classification. 
                                                          
1 Macao, Hong Kong, and Taiwan, which are all classified as high-income countries by the World Bank, were 
analysed separately from the mainland of the People’s Republic of China, an upper-middle-income country.  
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Types of economic evaluation 
Finally, we also used key term searches to disaggregate studies by self-reported type: CBA, CUA, and 
other CEAs. We further disaggregated cost-utility studies between those employing disability-adjusted 
life-years (DALYs) and those employing QALYs. Search terms are listed in Appendix 7. 
Institutional and geographic affiliations of authors 
We analyzed data on the institutional affiliation of all authors to develop a comprehensive picture of the 
institutions and countries contributing to health economic evaluations.  
We identified the top ten institutions within each income group by volume of economic evaluations 
produced. As in previous work (Wagstaff and Culyer, 2012, Rubin and Chang, 2003), schools, colleges and 
institutes were aggregated with the university to which they belonged, with the exception of the highly 
federal Universities of London, California, Texas, and other similar university systems, whose constituent 
members were analyzed separately.  
We considered a number of possible approaches for analysing articles with more than one institutional 
affiliation, including assigning a fractional value (and even weighted fractional values reflecting author 
order) to each institution based on the number of authors or institutions represented on a given article 
(Aksnes et al., 2012, Hagen, 2013, Retzer and Jurasinski, 2009). However, we rejected such approaches 
because the use of zero-sum metrics establishes a perverse incentive against collaboration between 
institutions and against the crediting of collaborators. We therefore assigned one point per institution per 
article, regardless of the number of institutions or authors on a given article. This has the disadvantage of 
weighting the analysis towards articles from multiple institutions, as these articles are counted multiple 
times in the analyses of institutional and country affiliations. More information on how we classified 
health areas and institutional affiliations is available in Appendix 5.  
 
4. Results 
4.1. Search results 
In total, our searches of the 14 databases identified 47,407 records (Appendix 1). After duplicate 
removal, 15,057 unique records remained. 12,213 articles were removed in screening, leaving a total of 
2,844 unique, full economic evaluations in the database.  
4.2. Databases 
Our search of Scopus identified the largest number of economic evaluations (n=2409), 85% of our total, 
followed by NHS EED, which identified 80% of the articles we identified (Appendix 8). Together, these 
two databases identified 96% of articles, and adding the Medline search increased this to 98%. With each 
additional database, the incremental gains were diminishingly small, and one database, Lilacs, failed to 
identify any additional articles beyond those identified by other databases.  Econlit identified just 42 
economic evaluations, 1% of the total. If we exclude NHS EED from consideration as it ceased to update 
records from March 2015 and exclude Wiley HEED as it ceased to be available from the end of 2014, our 
searches of a combination of Scopus, Medline, and Global Health would identify 91% of the economic 
evaluations, but a remaining 7% of economic evaluations in our database were only identified by NHS EED 
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and Wiley HEED not by our searches of other databases (Appendix 9). If we restrict the analysis to articles 
studying L&MICs and exclude NHS EED and Wiley HEED, our searches of Scopus, Medline, and Global 
Health would together identify 93% of economic evaluations in L&MIC settings, while 4% were only 
identified in NHS EED and Wiley HEED (Appendix 10).   
4.3. Subjects studied 
Geographic areas studied 
At least one country, region, and income group studied was identified for all economic evaluations 
identified. Of these, 2,350 (83%) studied high-income countries, 391 (14%) upper-middle-income 
countries, 121 (4%) lower-middle-income countries, and 104 (4%) low-income countries. These sum to 
more than 100% because 63 (2%) articles reported studies set in multiple countries in more than one of 
the four income groups. As expected, most articles reported findings from Europe & Central Asia (1243, 
44%) and/or North America (960, 34%), while relatively fewer articles reported findings from East Asia & 
Pacific, including Australia (405, 14%), Sub-Saharan Africa (158, 6%), Latin America and the Caribbean 
(129, 5%), South Asia (56, 2%), or the Middle East and North Africa (62, 2%). These figures include the 102 
(4%) articles which analyzed countries in more than one region (Table 1).  
Table 2 presents the individual countries most frequently studied. The United States was the subject of 
813 studies, followed by the United Kingdom (n=478) and six further countries which were each studied 
in at least 100 articles: the Netherlands (n=183), Canada (n=162), Spain (n=136), China (n=116), Germany 
(n=109), and Australia (n=100). While China, South Africa (n=71), and Brazil (n=56) were studied in a 
relatively large number of articles, only ten upper-MICs were studied in at least 20 articles each. Led by 
Uganda (n=49), India (n=41), Kenya (n=41), and Zambia (n=39), all of the top 20 LIC & lower-MICs were 
studied in more than 20 economic evaluations, in part because 61 of the 184 articles (33%) studying at 
least one LIC or lower-MIC examined more than one country and 33 LIC & lower-MIC articles (18%) 
studied more than ten countries. In upper-MICs and HICs, only 14% (n=54) and 7% (n=169) of studies, 
respectively, examined more than one country and 8% (n=32) and 1% (n=27) examined more than 10 
countries. 
Health areas studied and the global burden of disease 
At least one health area was assigned to 2,829 (99.5%) articles. The mean number of health areas per 
article was 1.4 and the maximum 7, reflecting a tendency towards evaluations addressing and often at 
the intersection of multiple health areas, as well as the construction of our health areas by which “lung 
cancer”, for example, would be categorized as both “cancer” and “respiratory”. In LICs, three health areas 
dominate: HIV/AIDS (30% of classified LIC articles), neonatal and maternal conditions (16%), and malaria 
(15%) (Table 3). In lower-MICs, HIV/AIDS again dominates (23%), but the remaining health areas are more 
evenly distributed; malaria comes second (11%), and is followed by other infectious diseases (8%) and 
mental health (8%); half of the latter focused on HIV treatment and prevention amongst injection drug 
users. In upper-MICs, HIV/AIDS (12%) falls to second place, while cancer and other neoplasms (19%) 
occupies the top spot with cardiovascular (11%) and respiratory diseases (10%) in third and fourth.  As 
HICs are studied in 83% of economic evaluations, the disease areas addressed in economic evaluations in 
HICs drive the distribution of all economic evaluations conducted worldwide, with cardiovascular diseases 
(19% in HICs), cancer and other neoplasms (18%), mental health (10%), and musculoskeletal diseases 
(10%), the leading areas of study in HICs and overall (Table 3).   
  WORKING PAPER: Economic evaluation in global perspective  Page 11 of 32 
The distribution of articles across health areas corresponds substantially but by no means perfectly with 
the global disease burden. The degree of correlation varies by income level, but also depends on whether 
rankings or proportions are compared. By either metric, the health areas studied in HICs correlate 
surprisingly well with disease burden and substantially better than economic evaluations in LICs, lower-
MICs, and upper-MICs, which feature more numerous and extreme outliers (Figure 1). As L&MICs account 
for 89% of the burden of disease and ill health, burden of disease correlates substantially less well with 
the health areas studied in economic evaluations globally than in HICs. 
Some health areas accounted for a substantially higher proportion of economic evaluations conducted 
than burden of disease. HIV/AIDS is studied in a greater proportion of economic evaluations at every 
income level than its share of the disease burden, however, the gap is much smaller in HICs than in LICs 
and lower-MICs, where it is an extreme outlier. Other such “winners” across all income levels include 
“other infectious diseases”; genitourinary diseases, contraception, and fertility; and, STDs (other than 
HIV). 
There are also some “losers”: disease areas which are the subject of a lesser share of economic 
evaluations than disease burden. Interventions to address wounds and injuries and, to a somewhat lesser 
extent, neurological conditions, appear to be substantially under-researched at every income level.   
4.4. Journals and languages 
Economic evaluations were published in a total of 967 different journals, which averaged 1.3 economic 
evaluations each per year (Appendix 11). 559 journals published only one economic evaluation each in 
the entire 28-month period we analysed and 165 journals published only two. Just as the number of 
economic evaluations decreases down the income levels, so too does the number of journals in which 
they are published, from 802 journals publishing HIC articles to just 44 publishing LIC articles. The 
proportion of articles published in the top 20 journals for each income group increases steeply down the 
income groups: 29% of articles studying HICs are published in the top 20 journals publishing HIC 
evaluations, while 77% of articles studying LICs are published in the top 20 journals publishing LIC 
evaluations.  
Overall, 74% of articles were published in biomedical rather than health economics, systems, and policy 
journals (22%) or other journal types (5%) (Figure 2).  In HICs, however, 6 of the top 10 journals were 
health economics, systems, or policy journals, compared with only 3 of the top 10 journals publishing 
articles about LIC & lower-MICs (Table 4). The top outlet for economic evaluations across all income 
levels was PLoS ONE, an open-access journal publishing “primary research from any scientific discipline”, 
which ranked first both for LIC & lower-MICs and for upper-MICs and third for HICs. Vaccine, which 
ranked fourth overall (n=66), ranked fifth for HICs (n=44) and second for both LIC & lower-MICs (n=13) 
and for upper-MICs (n=17). Yet overall, journals tended towards segregation by income group; 6 of the 
top 10 journals publishing economic evaluations about HICs did not publish a single LIC & lower-MIC 
study and two of the remaining published only one each.  
All articles addressing LICs and lower-MICs were published in English, while 4% of HIC articles (n=89) were 
published in other languages, as was a striking 22% (n=87) of all articles addressing upper-MICs. In upper-
MICs, Chinese was the leading non-English language (n=48, 12%), followed by Spanish, (23, 6%), and 
Portuguese (n=13, 3%), Turkish (n=2, 1%), and Farsi (n=1, 0%), while in HICs, Spanish was the language of 
full-text for 46 articles (2%), followed by German (n=13, 1%), and ten other languages.  
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4.5. Types of economic evaluation 
Although the term is widely (mis)used in the literature, genuine cost-benefit analyses are very rare; we 
excluded many articles from our database which described themselves as CBAs of health interventions 
but did not value health or welfare outcomes. Of the 147 (5%) articles in our database which described 
themselves as CBAs, some do not in fact place a monetary value on health outcomes and should probably 
be described as CEAs or CUAs, however, for consistency and feasibility, our analysis of evaluation type is 
based on key term searches, and therefore reflect the authors’ classification (Appendix 7). Cost-utility 
analyses accounted for at least half of economic evaluations across all income levels, ranging from 50% 
(n=52) in LICs to 62% (n=1448) in HICs. The proportion of CUAs employing DALYs decreases from 87% 
(n=45) in LICs to 2% (n=35) in HICs, while the proportion employing QALYs increases from 13% (n=7) in 
LICs to 35% (n=23) in lower-MICs, 68% (n=123) in upper-MICs, and 96% (n=1385) in HICs.   A very small 
proportion of studies described themselves as CUAs but did not contain any search terms for DALYs or 
QALYs. (Figure 3, Appendix 12)  
4.6. Authors’ geographic and institutional affiliations 
Author affiliation data were obtained for all articles. At least one author was affiliated with an institution 
in the United States or the United Kingdom on 1,145 (40%) and 619 (22%) of articles, respectively (Table 
5). The Netherlands came in third place, as the country affiliation of at least one author of 9% of articles 
(n=267). With 116 articles, China-based authors contributed to 4% of all articles, making it the ninth 
largest contributor to economic evaluations, while Brazil (51, 2%) and South Africa (49, 2%) also ranked 
within the top 20 country affiliations of authors. With 22 articles (1%), India was the highest ranked 
lower-MIC and ranked 29th overall, just ahead of Hong Kong and Singapore, while Uganda was the largest 
contributor to economic evaluations amongst LICs with 20 articles (1%) and ranked 32nd overall just ahead 
of New Zealand. In general, the lists of leading country affiliations of authors within each income group 
strongly resemble the leading countries studied, however, the disparity between the top few countries 
and others are even more extreme; for example, while 813 articles studied the United States and 49 
studied Uganda, United States-based authors contributed to 1,145 articles, whereas Uganda-based 
authors only contributed to 20.  There were 30 articles set in Uganda which did not include any Uganda-
based authors; of these, 25 were studies set in at least 15 countries each, but 5 articles focused on 3 or 
fewer countries.  
On 91% of articles, at least one author was based in a high-income country. (Table 6) All but 5 of the 2350 
articles studying HICs included at least one author based in a HIC and most articles studying upper-MICs 
included at least one upper-MIC-based author (n=338, 86%). By contrast, only 53% and 54% of articles 
studying LICs and lower-MICs, respectively, included any author based in an institution in the respective 
income group.  Authors based in upper-MICs contributed to a relatively small proportion of articles 
analyzing LICs (n=16, 15%) or lower-MICs (n=15, 12%), and in nearly half of these articles, upper-MICs 
were also studied. Authors based in HIC institutions contributed to 94% (n=98) of articles analyzing LICs 
and 82% (n=99) analyzing lower-MICs, compared with fewer than half of evaluations in upper-MICs 
(n=175, 45%). Of the 65 articles studying LIC & lower-MIC which did not include an author from those 
income levels, 44 articles included at least one author based in the United States (68%).  At least one 
author listed a major pharmaceutical company amongst the institutional affiliations on 9% of articles 
(n=246) overall, varying from 9% (n=221) of articles studying HICs, to 12% (n=46) studying an upper-MIC, 
7% (n=8) studying a lower-MIC and 4% (n=4) studying a LIC. The leading institutions in LICs, lower-MICs, 
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and HICs contributing to economic evaluations were Anglophone, with the exceptions only of the 
Netherlands (where English is widely spoken) and Vietnam; this is in contrast to the leading upper-MICs, 
including China, Brazil, Thailand, Colombia, and Mexico, with South Africa as the only country in which 
English is an official language.  
Harvard University, including its affiliated hospitals, was by some distance the institution contributing to 
the largest number of economic evaluations (n=152). The top institutions producing economic 
evaluations in LIC & lower-MICs are notable for their low individual and collective output, as well as for 
including many ministries of health or (semi-)autonomous research institutes (Table 7).  The leading LIC 
or lower-MIC institution, Makerere University, was listed amongst the author affiliations of 14 economic 
evaluations over the 2.3 years we studied. The World Health Organization was listed amongst the author 
affiliations on 25 articles, while the World Bank and United Nations’ Children’s Fund contributed to only 4 
economic evaluations each. 
 
5. Discussion 
Our analysis provides an evidence base from which to discuss the current state of the economic 
evaluation field and has generated many questions which warrant further investigation. Some of these 
issues are examined in other papers.  For example, Griffiths and colleagues compare the methods used in 
economic evaluations in countries of differing income groups in a representative sample of articles from 
the database we created (2015) and Harker and Guinness examine the growing use of QALYs in L&MICs 
(Harker and Guinness, 2015). Other articles examine issues around capacity to produce and to use 
economic evaluations in Central and Eastern Europe (Kalo et al., 2015) and in a number of countries in 
Asia and Latin America (Tantivess et al., 2015). Our analysis also offers insights to strengthen the process 
of prioritising, conducting, publishing, and developing capacity for economic evaluation research. Here, 
we discuss the state of the field and the implications of our findings for research priority setting and 
capacity development. 
5.1. The state of health economic evaluation 
We identified a large volume of economic evaluations – 2,844 over 28 months – including 1,273 in 2013 
alone. The principal economics database, EconLit, contains 5,483 publications with “Health” JEL codes for 
2012 and 2013, but captured just 1% of economic evaluations published in those years. A large majority 
of economic evaluations were published in biomedical journals and even many of the journals we 
categorized as “health economics, services, and policy” are not indexed in EconLit. Adding the 2,413 
economic evaluations we identified for 2012 and 2013 to the EconLit “health” records would increase the 
volume of “health economics” research by 44%. Further, these publications still do not include the many 
other health economic analyses of, for example, equity, demand, markets, and incentives, which are 
published in journals outside the economics literature as defined by the EconLit database.  
Despite important analytical differences and the lack of overlap between the body of literature addressed 
in our analysis and Wagstaff and Culyer’s analysis of health economics within the EconLit database, our 
findings share some commonalities. Both our analyses identified Harvard as the leading institution and 
the United States as by far the most prolific contributor to health economic (evaluation) research, 
followed by the United Kingdom, and then the Netherlands, Canada, and Australia. China and South 
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Africa also rank highly in both our analyses. Nonetheless, our findings also differ in important ways. As 
expected, our lists of leading journals share very little in common, as economic evaluations are 
predominantly published in biomedical journals, which are not indexed in EconLit. Some contributors, 
such as the World Bank and Taiwan, which ranked very highly in Wagstaff and Culyer’s analysis, 
contribute far less to economic evaluations, while institutions with a stronger focus on health (rather 
than only economics) tend to rank more highly in our analysis. There are also substantial differences with 
respect to our estimates of the volume of research. Whereas Wagstaff and Culyer find that “economic 
evaluation . . .[shows] no clear trend”, our analysis has highlighted the substantial size of the applied 
health economic evaluation literature relative to the “health economics” literature within EconLit, and 
indicates that with just 1% of the applied economic evaluation literature, the EconLit database is unlikely 
to provide a representative indication of trends over time in the size or relative importance of health 
economic evaluation.           
As previously highlighted (Wagstaff and Culyer, 2012), identifying health economic literature in the 
biomedical databases was not straightforward.   We found the use of economic vocabulary and article 
classifications in biomedical journals and databases to be so poor and inconsistent as to render 
simultaneously sensitive and specific searching impossible (Appendix 3). The NHS EED database, while 
incomplete, was by far the most sensitive and specific source of economic evaluations, which makes the 
decision to cease to update it from March 2015 particularly lamentable. The ongoing work to add DALY-
based cost-utility analyses to the existing QALY-based Tufts Economic Evaluation Registry is a welcome 
development, however, it will still omit half of economic evaluations conducted in L&MICs and currently 
charges for access. 
Our findings paint a picture of a research community that is simultaneously highly concentrated in a few 
countries and institutions and highly fragmented. A very small number of journals publish economic 
evaluations from both high- and low-income settings and a large proportion of articles appear in journals 
which only very rarely publish economic evaluations. The fact that so many biomedical journals now 
publish economic evaluations (if only rarely) is a positive sign of the acceptance and integration of 
economic evaluation within health research. It is also perhaps unsurprising, as economic evaluations are 
usually oriented towards health sector decision makers. This fragmentation may, however, also explain 
some of the problems of quality highlighted elsewhere (Griffiths et al., 2015), as biomedical journal 
editors may not only lack specialist knowledge of economic evaluation methods, but also lack familiarity 
with pools of suitably qualified reviewers. In this way, the small number of journals publishing economic 
evaluations about L&MICs may present an opportunity to engage with the editors of these journals to 
help improve standards where necessary, whereas the vast array of authors, institutions, and journals 
associated with economic evaluations set in HICs presents a somewhat different challenge. In any case, 
the lack of scholarly dialogue between those focusing on countries of differing income levels seems likely 
to be detrimental to all.   
We hope that recognition of the size, importance, and fundamental interdisciplinarity of health economic 
evaluation will lead to an evolution in research culture within the field, and also, on a practical level, to 
improvements in existing databases or creation of a new one that will better reflect and serve the needs 
of health economics researchers. Of course, authors themselves, reviewers, and editors could already do 
far more to facilitate the efficient identification of health economic evaluations. For example, an initial 
step could include ensuring that all articles include the study design in their title, as is already required by 
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Plos Medicine, and that those that are not economic evaluations avoid economic terminology, such as 
“cost-effective” in their titles, abstracts, and keywords.   
5.2. Research priority setting 
Our findings also raise a number of questions about the health and geographic areas that are and are not 
prioritized for health economic evaluation. Burden of disease is not and should not be the sole 
determinant of the volume of economic evaluation research.  It seems difficult to argue, however, that 
the differences between the number of economic evaluations conducted across low-, middle-, and high-
income countries is equitable or efficient. High-income countries account for 15.8% of the world’s 
population, 10.9% of the global burden of disease (World Health Organization., 2014), and 82.6% of all 
economic evaluations conducted, while low-income countries account for 11.7% of the world’s 
population, 19.3% of the global burden of disease, and 3.7% of economic evaluations.  There are 139 
different L&MICs (World Bank, 2015), which have very diverse epidemiological and economic 
characteristics, and also, in many cases, weak(er) health systems with substantial and diverse constraints 
on the supply and demand for health care; this diversity likely contributes to greater heterogeneity in the 
cost-effectiveness of interventions and necessitates more, not less, research.(Vassall et al., 2015) Further, 
the opportunity cost of incorrect priority setting decisions may be substantially higher in low-income 
settings than in high-income settings. 
One of our most surprising findings is how well the health areas studied in HICs correlate with the burden 
of disease in those settings. In L&MICs, however, the picture is much more mixed, with many more 
economic evaluations conducted about health areas accounting for lower proportions of the burden of 
disease. There are several reasons why such discrepancies may not be inequitable or inefficient. First, the 
GBD estimates themselves are highly contested (Nord, 2013, Byass et al., 2013); intended to reflect only a 
very narrow definition of health consequences, the newest disability weights used in the GBD estimates 
exclude wider individual or social welfare consequences (Salomon et al., 2012).  In the case of HIV/AIDS, 
for example, the many and varied stakeholders could therefore conclude that it is right that HIV should be 
studied more than health areas accounting for a larger burden of disease because of its wider social and 
economic consequences, or because its health consequences are only lower than other diseases because 
of ongoing and expensive control efforts.  Second, some health areas may have a low value of additional 
information relative to the costs of generating the information, especially if extensive research has 
already been conducted in that area. Third, so little may be understood about some health problems at a 
clinical level that economic evaluation of interventions may be premature. Fourth, economic evaluations 
may be conducted not to consider adding another more effective and more costly intervention, but 
rather to consider divestment from costly interventions, and therefore economic evaluations in health 
areas that contribute very little to the disease burden may be warranted. Finally, as economic evaluations 
are conceptualized around a (package of) interventions, which may not map neatly onto specific 
conditions, categorization of economic evaluations by health areas also has some conceptual limitations 
which could weaken their correlation with disease burden; we found this to be particularly true for 
surgical procedures, pain management and palliative care, and health systems and intersectoral 
interventions.  
On the other hand, the four health areas accounting for the largest burden of disease in LICs are: 1) 
Neonatal and maternal conditions, 2) Respiratory diseases, 3) Wounds and injuries, and 4) Diarrhoeal 
diseases. While further biomedical advances, such as a point-of-care test for bacterial infections would 
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help (Zumla et al., 2014), the bulk of the impact of all four of these health areas needs to be addressed 
through health systems, multi-sectoral, and/or social interventions such as prompt access to high-quality 
health facilities (Kerber et al., 2007), road safety measures (World Health Organization., 2013), and 
improved water and sanitation (Bartram et al., 2005). Such solutions offer little potential for 
pharmaceutical company profits and instead require complex interventions. Recent systematic reviews of 
economic evaluations of cardiovascular disease interventions in L&MICs similarly found that evaluations 
of pharmacological interventions dominated and a greater focus on evaluation of non-clinical strategies 
was needed.(Shroufi et al., 2013, Suhrcke et al., 2012) Financing such evaluations is unlikely to appeal to 
private for-profit companies, and so domestic and international research funders, as well as researchers 
themselves, should concentrate on producing research in these areas, and thereby correct this market 
failure. 
5.3. Capacity development 
Several of our findings have important implications for thinking about how to increase capacity to 
produce and to use high-quality and policy-relevant health economic evaluations. Large upper-MICs, 
especially China but also South Africa, Brazil, and Iran, produce substantial numbers of economic 
evaluations and far more than many smaller HICs. This is in some ways unsurprising, as the costs of 
research are independent of the size of a country’s population or economy and so the relative costs of 
research are lower in large economies. Capacity development is important for all countries, but 
particularly challenging for L&MICs and for small HICs as well (Kalo et al., 2015). A large gap between the 
numbers of economic evaluations conducted and what is needed for priority setting persists in all but a 
few countries (Geroy, 2012, Odame, 2013, Mori and Robberstad, 2012).   
Our analysis has identified some clear institutional leaders in low- and middle-income countries, but also 
highlighted that many countries produce few, if any, economic evaluations. We propose the development 
of strong regional or sub-regional networks which bring together existing capacity in health economic 
evaluation and build on centres of strength in health intervention research, even where substantial 
economic evaluation capacity may not yet exist. A multi-stakeholder report on how to strengthen health 
economics more generally in Africa highlighted the importance of international networks as well as local 
institutional support (McIntyre et al., 2008). In addition to training and ongoing technical support, a well-
funded regional network could also offer scope for deeper collaboration in producing multi-country 
evaluations and assessing transferability of findings across the region. Such a regional approach could be 
more efficient in generating economic evidence and assessing its relevance to a wider range of settings 
more systematically.  
The leading contributors to economic evaluations from low- and lower-middle-income countries tend to 
be research institutions, often within or associated with Ministries of Health, rather than universities. 
Such embeddedness should be an advantage in ensuring that research both reflects and informs a 
country’s health priorities. It also means, however, that there may be no pre-existing link between those 
who conduct health economic evaluation research and those who teach and train undergraduate and 
postgraduate students in these countries. This marked difference from high- and even upper-MICs may 
require new approaches to capacity development, rather than replication of strategies that have achieved 
successes in upper-MICs and HICs.   
At the same time, further work is needed to generate demand for economic evaluation through the 
institutionalization of priority setting at the national level (Odame, 2013, Mori and Robberstad, 2012, 
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Wiseman et al., 2015), as well as continuing to strengthen the role of economic evaluation in 
international policy making at the World Health Organization, whose policy recommendations play a 
particularly large role in low- and lower-middle-income countries (World Health Organization., 2012). 
Finally, nearly half of economic evaluations studying LICs and lower-MICs do not include any authors from 
L&MIC institutions. Some of these were desk-based modelling studies, however, many involved data 
collection in L&MICs. Some may have included authors from L&MICs affiliated with a HIC institution, for 
example, as doctoral students, however, such cases cannot explain the full magnitude of the discrepancy. 
It is unclear whether this discrepancy reflects a lack of opportunities for participation from fellow 
researchers or funders, lack of skills or incentives, or some combination of these and other factors, but 
the results are clearly inequitable.(Chu et al., 2014)  The situation also suggests a failure to recognize the 
wider potential of research capacity development to improve health in L&MICs and the more immediate 
impact that real partnership with L&MIC researchers and policy makers can have in ensuring that the 
research is policy-relevant and informs policy decisions. Both funders and researchers in all countries 
must examine and address these inequities. 
We hope that the findings of this analysis will be useful for those conducting (systematic) reviews of the 
economic evaluation literature and that they will encourage and provide an empirical grounding for 
debate on the current state and future directions for this growing field. 
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Table 1 Number of economic evaluations by income group and region of study 
 Income group(s) of countries studied 
Region(s) studied Low  Lower-
middle 
Upper-
middle 
High Multiple*  Total % of total 
East Asia & Pacific  22 43 165 229 25 405 14% 
Europe & Central Asia  11 16 44 1210 20 1243 44% 
Latin America & Caribbean 13 18 116 16 19 129 5% 
Middle East & North Africa  14 20 43 27 20 62 2% 
North America 1 1 1 960 1 960 34% 
South Asia 27 49 20 15 25 56 2% 
Sub-Saharan Africa  92 64 78 22 46 158 6% 
Multiple*  27 35 31 85 38 102 4% 
Total 104 121 391 2350 63 2844 100% 
% of total 4% 4% 14% 83% 2% 100%  
*Articles studying at least two countries of differing income levels or regions are categorized as “Multiple”.  
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Table 2 Top 20 countries most frequently studied in economic evaluations by income group 
 
 High income Upper-middle-income Low and lower-middle-income 
Rank Country N % Country N  Country N  
1 United States 813 35% China 116 30% Uganda 49 27% 
2 United Kingdom 478 20% South Africa 71 18% India* 41 22% 
3 Netherlands 183 8% Brazil 56 14% Kenya* 41 22% 
4 Canada 162 7% Thailand 36 9% Zambia 39 21% 
5 Spain 136 6% Iran 31 8% Malawi 35 19% 
6 Germany 109 5% Colombia* 28 7% Nigeria* 34 18% 
7 Australia 100 4% Mexico* 28 7% Tanzania* 34 18% 
8 Italy 98 4% Turkey 24 6% Zimbabwe 33 18% 
9 Sweden 74 3% Botswana* 23 6% Congo, Dem. Rep. 30 16% 
10 France 57 2% Namibia* 23 6% Ethiopia 29 16% 
11 Japan 45 2% Angola 18 5% Lesotho* 28 15% 
12 Belgium 42 2% Gabon 17 4% Mozambique* 28 15% 
13 Denmark 33 2% Mauritius* 14 4% Rwanda* 28 15% 
14 Korea, Rep.* 31 1% Peru* 14 4% Vietnam* 28 15% 
15 Norway* 31 1% Seychelles* 14 4% Ghana 27 15% 
16 Greece 29 1% Bulgaria 13 3% Central African Republic 26 14% 
17 Ireland 27 1% Argentina* 12 3% Burundi* 25 14% 
18 Switzerland* 24 1% Hungary* 12 3% Cameroon* 25 14% 
19 Finland* 24 1% Maldives 11 3% Eritrea* 25 14% 
20 Taiwan 23 1% Serbia 10 3% Burkina Faso 24 13% 
High-income 
countries 2350 100% 
Upper-middle-
income countries 391 100% 
Low- and lower-middle-
income countries 184 100% 
*Equal ranking with country above and/or below. 
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Table 3 Number of economic evaluations by health area and income group 
A single economic evaluation may address more than one health area in countries of more than one 
income group. The totals exclude the 15 articles (0.5%) in our data set which could not be classified 
by health area. 
 Income group studied 
Health area Low Lower-
middle 
Upper-
middle 
High World 
Cancer and other neoplasms 7 8 73 416 492 
Cardiovascular diseases 3 7 44 448 490 
Mental health, cognition, and developmental and 
behavioural disorders (including self-harm and 
substance disorders)  
1 10 21 243 268 
Musculoskeletal diseases (including back pain) 2 3 18 240 262 
Respiratory diseases 6 8 39 188 228 
Genitourinary diseases, contraception & fertility 4 4 18 180 203 
Other infectious diseases (including encephalitis, 
hepatitis, other parasitic and vector-borne diseases, 
and nematode infections) 
6 10 38 111 159 
Digestive disorders 3 3 21 127 152 
Neonatal and maternal conditions 17 7 23 102 142 
HIV/AIDS 31 27 46 61 136 
Diabetes 1 3 22 102 125 
Malnutrition (including obesity and exercise) 6 4 9 98 113 
Wounds and injuries (including violence) 4 7 13 91 109 
Endocrine, blood, and immune disorders (not 
diabetes or HIV) 
0 1 12 86 99 
Neurological conditions 1 3 16 81 98 
Skin and oral conditions 0 3 5 67 75 
Sense organ diseases 2 3 11 56 68 
Tuberculosis 8 9 28 34 62 
Sexually transmitted diseases (not HIV) 2 1 10 39 49 
 Diarrhoeal diseases  6 7 9 29 46 
Communicable childhood diseases 2 5 9 24 40 
Malaria 16 13 8 1 24 
Congenital anomalies 0 1 2 20 23 
Anaemia 0 1 1 9 11 
Meningitis  2 2 3 3 9 
TOTAL 104 120 390 2,337 2,829 
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Table 4 Journals publishing the greatest number of economic evaluations by income group of countries studied 
 Low and lower-middle Upper-middle High income  All 
Rank Journal Type N Journal Type N Journal Type N Journal Type N 
1 PLoS One Other 30 PLoS One Other 31 Journal of Medical Economics HEPS 100 PLoS One Other 121 
2 Vaccine BM 13 Vaccine Other 17 Health Technology Assessment HEPS 82 Journal of Medical Economics HEPS 101 
3 Malaria Journal BM 9 Value in Health Regional Issues BM 11 PLoS One Other 70 Health Technology Assessment HEPS 82 
4 
Journal of Acquired Immune 
Deficiency Syndromes BM 8 Value in Health HEPS 8 Value in Health HEPS 54 Vaccine BM 66 
5 Health Policy and Planning HEPS 8 BMJ HEPS 7 Vaccine BM 44 Value in Health HEPS 63 
6 
BMJ BM 6 AIDS BM 7 
ClinicoEconomics and Outcomes 
Research HEPS 36 
ClinicoEconomics and Outcomes 
Research HEPS 37 
7 
Value in Health Regional 
Issues HEPS 6 Cadernos de Saude Publica BM 7 European Journal of Health Economics HEPS 35 
European Journal of Health 
Economics HEPS 36 
8 
Cost Effectiveness and 
Resource Allocation HEPS 5 BMC Public Health BM 6 
PharmacoEconomics 
HEPS 33 
PharmacoEconomics 
HEPS 34 
9 PLOS MEDICINE BM 5 BMC Health Services Research BM 6 Clinical Therapeutics BM 28 Clinical Therapeutics BM 32 
10 AIDS BM 4 PLoS Medicine HEPS 5 BMJ Open BM 26 Value in Health Regional Issues HEPS 28 
11 
PloS Neglected Tropical 
Diseases BM 4 
International Journal of Tuberculosis 
and Lung Disease BM 5 
Applied Health Economics and Health 
Policy HEPS 26 BMJ Open BM 26 
12 
BMC Public Health BM 3 
Journal of the Medical Association 
of Thailand BM 5 
International Journal of Technology 
Assessment in Health Care HEPS 22 
Applied Health Economics and 
Health Policy HEPS 26 
13 
International Journal of 
Tuberculosis and Lung 
Disease BM 3 Malaria Journal BM 4 Cancer BM 21 
International Journal of Technology 
Assessment in Health Care HEPS 25 
14 
World journal of surgery 
BM 3 
Journal of Acquired Immune 
Deficiency Syndromes BM 4 BMJ BM 19 BMC Health Services Research HEPS 23 
15 
Bulletin of the World Health 
Organization HEPS 3 
Cost Effectiveness and Resource 
Allocation BM 4 BMC Health Services Research HEPS 17 Cancer BM 21 
16 
Tropical Medicine and 
International Health BM 3 Clinical Therapeutics HEPS 4 American Journal of Managed Care BM 16 BMJ BM 20 
17 Clinical Infectious Diseases BM 2 BMC infectious diseases BM 4 Osteoporosis International BM 14 BMC Public Health BM 20 
18 
Lancet BM 2 
Revista Panamericana de Salud 
Publica BM 4 Gynecologic Oncology BM 14 
Cost Effectiveness and Resource 
Allocation HEPS 20 
19 Biosystems BM 2 Modern Preventive Medicine BM 4 BMC Public Health BM 13 American Journal of Managed Care BM 16 
20 
Journal of Pediatrics BM 2 Biomedica BM 4 
Cost Effectiveness and Resource 
Allocation HEPS 13 AIDS BM 16 
 Lancet Global Health BM 2 Chinese Journal of New Drugs BM 4 BJU International BM 13    
 
Proceedings of the National 
Academy of Sciences of the 
USA BM 2 
Zhonghua liu xing bing xue za zhi 
BM 4 Heart BM 13 
   
 
Journal of the Pakistan 
Medical Association BM 2 
         
 Disasters Other 2          
BM: Biomedical; HEPS: Health economics, policy, and services; OTH: Other.  
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Table 5 Most frequent countries of institutional affiliation of authors 
The table ranks countries of institutional affiliations of authors by the number of economic 
evaluations including at least one author affiliated with that country. All countries affiliated with at 
least one author of at least one economic evaluation are listed. *Equal ranking with country above and/or 
below.   
  High-income   Upper-middle-
income 
Low- and lower-middle-
income 
Rank Country N Country N Country N 
1 United States 1145 China 116 India 22 
2 United Kingdom 619 Brazil 51 Uganda 20 
3 Netherlands 267 South Africa 49 Kenya 13 
4 Canada 238 Thailand 37 Vietnam 11 
5 Australia 191 Colombia 32 Ghana* 9 
6 Germany 151 Mexico 26 Zambia* 9 
7 Spain 147 Iran 25 Nigeria 8 
8 Switzerland 104 Turkey 18 Indonesia* 5 
9 France 103 Argentina 14 Burkina Faso* 5 
10 Italy 99 Malaysia 12 Bangladesh* 4 
11 Sweden 98 Peru 9 Pakistan* 4 
12 Belgium 78 Bulgaria* 7 Tanzania* 4 
13 Japan 53 Serbia* 7 Philippines* 4 
14 Denmark 45 Hungary 5 Egypt* 4 
15 Ireland 39 Venezuela 3 Ethiopia* 2 
16 Norway 32 Romania* 2 Malawi* 2 
17 Taiwan 28 Lebanon* 2 Congo, Dem. Rep.* 2 
18 Finland 27 Costa Rica* 2 Benin* 2 
19 Korea, Rep.* 25 Jordan* 2 Myanmar* 2 
20 Austria* 25 Tunisia* 2 Zimbabwe* 2 
21 Greece 23 Iraq* 1 Cameroon* 2 
22 Hong Kong 21 Botswana* 1 Senegal* 2 
23 Singapore 21 Cuba* 1 Sri Lanka* 1 
24 New Zealand* 19 Kazakhstan* 1 Cambodia* 1 
25 Poland* 19 Panama* 1 Niger* 1 
26 Portugal 15 Jamaica* 1 Afghanistan* 1 
27 
Israel 12 
Dominican 
Republic* 1 
Nepal* 1 
28 Russia 9   Rwanda* 1 
29 Chile 8   Sierra Leone* 1 
30 Czech Republic 7   Somalia* 1 
31 Slovenia* 5   Syria* 1 
32 Qatar* 5   Bolivia* 1 
33 Croatia* 2   Guyana* 1 
34 Saudi Arabia* 2   Uzbekistan* 1 
35 Estonia* 2   West Bank and Gaza* 1 
36 Iceland*, 
Liechtenstein*, 
Lithuania*, 
Macao*, Malta*, 
Puerto Rico*, 
Trinidad and 
Tobago*  1     
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Table 6 Income group studied vs. Income group of author affiliations 
Row percentages are presented and reflect the proportion of articles addressing a given income level which include authors affiliated with institutions based 
in a country of the given income level. As all institutional affiliations of all authors of a given article are analyzed, and a single article may examine countries in 
more than one income group, column totals and row totals may be less than the sum of the given column or row.   
 Income group of authors' country affiliation(s) 
Income group of 
countries studied 
Low  Lower-middle  Upper-middle High Total 
Low  55 (53%) 7 (7%) 16 (15%) 98 (94%) 104 (100%) 
Lower-middle  8 (7%) 65 (54%) 15 (12%) 99 (82%) 121 (100%) 
Upper-middle 11 (3%) 11 (3%) 338 (86%) 175 (45%) 391 (100%) 
High 4 (0%) 12 (1%) 51 (2%) 2345 (100%) 2350 (100%) 
Total 59 (2%) 80 (3%) 394 (14%) 2601 (91%) 2844 (100%) 
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Table 7 Most frequent institutional affiliation of authors 
The table ranks institutional affiliations of authors by the number of economic evaluations including at least one author affiliated with that institution. The 
top ten institutions located in each income level are listed. To the extent possible, institutions’ totals include their affiliated hospitals, centres, and groups 
even if the parent institution was not specifically cited in the affiliation data. *Equal ranking with country above and/or below. 
Income group of authors’ institutions 
  High Upper-middle Low and lower-middle 
 Rank Institution Country N Institution Country N Institution Country N 
1 Harvard University United States 152 University of Cape Town South Africa 19 Makerere University Uganda 14 
2 Johns Hopkins University United States 74 Tehran University of Medical 
Sciences 
Iran 17 Kenya Medical Research 
Institute 
Kenya 9 
3 London School of Hygiene 
& Tropical Medicine 
United Kingdom 70 Shanghai Jiao Tong University* China 15 Ministry of Health Vietnam 6 
4 University of Toronto Canada 65 Universidade de Sao Paulo* Brazil 15 All India Institute of Medical 
Sciences* 
India 5 
5 University of Amsterdam Netherlands 62 University of the Witwatersrand* South Africa 15 Hanoi Medical University* Vietnam 5 
6 University College 
London 
United Kingdom 61 Chinese Center for Disease 
Control and Prevention* 
China 11 Ghana Health Service* Ghana 4 
7 University of York United Kingdom 57 Mahidol University* Thailand 11 Ministry of Health* Zambia 4 
8 Pfizer, inc. Multinational 
private company 
51 Instituto Mexicano del Seguro 
Social* 
Mexico 10 University of Nigeria* Nigeria 4 
9 Centers for Disease 
Control and Prevention* 
United States 46 Universidad Nacional de 
Colombia* 
Colombia 10 Centre Muraz* Burkina Faso 3 
10 Duke University* United States 46 Health Intervention and 
Technology Assessment Program 
Thailand 8 Family Health* International Vietnam 3 
       INDEPTH Network* Ghana 3 
       Kenya Government Medical 
Research Center* 
Kenya 3 
       Mbarara University of Science 
and Technology* 
Uganda 3 
       Ministry of Health* Kenya 3 
       Universitas Padjadjaran* Indonesia 3 
       University of Ghana* Ghana 3 
       YR Gaitonde Centre for AIDS 
Research and Education* 
India 3 
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Figure 1 Economic evaluations vs. burden of disease by income group 
Results are presented in two ways: the lefthand column compares the ranking of the 25 health areas by the volume of 
economic evaluations and by burden of disease, while the righthand column compares the proportion of the total number 
of economic evaluations examining each health area with the proportion of the total burden of disease accounted for by 
each health area. MNH: Maternal and newborn health, STDs: Sexually transmitted diseases (excluding HIV), CVD: 
Cardiovascular disease, TB: Tuberculosis, Child: Communicable childhood illnesses. 
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Figure 2 Proportion of economic evaluations by journal type and income group 
 The classification of journals by type is provided in Appendix 6. Articles are disaggregated by the income group(s) of the country or countries studied. 
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Figure 3 Proportion of economic evaluations by analytical type and income group studied 
In this figure, “cost-effectiveness analyses” refers to articles meeting our definition of a full economic evaluation but not containing any keywords to define it more specifically as a cost-utility 
or cost-benefit analysis. Articles can be classified as both cost-utility and cost-benefit analyses if they contain keywords for both. CBA: Cost-benefit analysis, CEA: Cost-effectiveness analysis, 
CUA: Cost-utility analysis, DALY: disability-adjusted life year, QALY: quality-adjusted life-year. Articles are disaggregated by the income group(s) of the country or countries studied. 
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8. Appendices: Supplementary information on methods and results 
 
Appendix 1 Flow diagram of the data development process 
Appendix 2 Searches in bibliographic databases 
Appendix 3 A note on database indexing terms 
Appendix 4 Mapping of 25 disease areas onto the Global Burden of Disease (GBD), International 
Classification of Disease (ICD-10), and search terms used 
Appendix 5 Supplementary information on article classification 
Appendix 6 Classification of journal types 
Appendix 7 Search terms to classify cost-utility and cost-benefit analyses 
Appendix 8 Search findings by database – all articles and databases 
Appendix 9 Search findings by database – excluding NHS EED and Wiley HEED 
Appendix 10 Search findings by database – only articles studying low- and middle-income countries, 
excluding NHS EED and Wiley HEED 
Appendix 11 Journal concentration by income group of countries studied  
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Appendix 1 Flow diagram of the data development process 
The figure is adapted from the flow diagram recommended in the PRISMA statement on systematic reviews 
(Liberati et al., 2009). The “eligibility” stage recommended by PRISMA is not used here as articles were not 
reviewed for quality; decisions to include records were based primarily on the record’s source, title, and 
abstract; the full text was only screened where the title was unclear and the abstract was not available in any 
of the downloaded data. 
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47,407 records identified  
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12,213 unique 
records 
excluded: not 
full health 
economic 
evaluations 
14 databases electronically searched: 
Medline including in-process (7,566); 
Embase (7,558);  
EconLit (186);  
PsycInfo (808);  
LILACS (132);  
Cinahl (2,580);  
SSCI & SCI extended  (8,738);  
Biosis (2,643);  
Scopus (9,006);  
Scielo (162);  
Global Health (2,219);  
NHS EED (3,634);  
HEED (2,175). 
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Appendix 2 Searches in bibliographic databases 
Database (Interface) Search 
National Health 
Service Economic 
Evaluation 
Database (Centre 
for Reviews and 
Dissemination) 
 
Note: this database 
is still available, 
however, updating 
ceased in March 
2015 
NHS EED: tick box (DARE: blank, HTA: blank) 
Publication year: 2012 to 2014 
 
Export: “Full record”  produces a single RIS document with consecutively numbered records 
Health Economic 
Evaluations 
`Database (Wiley) 
 
Note: this database 
ceased to be 
available from the 
end of 2014. 
Search 1: Identifies studies already reviewed and categorized by HEED 
Search type (from purple button on left): Compound Search 
Use pull-down menus to select: 
| Journal Date | >= 2012 | AND | 
|Type of Econ eval | 'EFFECTIVENESS' Or 'UTILITY' Or 'BENEFIT' | AND | 
| Type of Article | ‘APPLIED’ |  
 
Search 2: Identifies additional studies not yet reviewed and categorized by HEED 
Search type (from purple button on left): Expert Search 
 
1. EE= 'EFFECTIVENESS'  Or  'UTILITY'  Or  'BENEFIT' AND TE= 'APPLIED'  AND JD>= 2012 
2. TI='Cost-effective*' OR 'Cost-Utility' OR 'Cost-benefit' OR 'Cost effective*' OR 'Cost Utility' OR 'Cost benefit' OR 'economic 
evaluation' AND (JD>= 2012 ) 
3. AB='Cost-effectiveness' OR 'Cost-Utility' OR 'Cost-benefit' OR 'Cost effectiveness' OR 'Cost Utility' OR 'Cost benefit' OR 
'economic evaluation' AND (JD>= 2012 ) 
4. KW='Cost-effectiveness' OR 'Cost-Utility' OR 'Cost-benefit' OR 'Cost effectiveness' OR 'Cost Utility' OR 'Cost benefit' OR 
'economic evaluation' AND (JD>= 2012 ) 
5. AB='cost per death averted' or 'cost per death avoided' or 'cost per case averted' or 'cost per case avoided' or 'cost per 
infection' or 'cost per life' or 'cost per disability-adjusted' or 'cost per quality-adjusted' or 'cost per qaly' or 'cost per daly' 
6. CS = LINE 1 OR LINE 2 OR LINE 3 OR LINE 5 
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LILACS 
(Bireme/WHO/ 
PAHO) 
cost-effective or "cost effective" or cost-effectiveness or "cost effectiveness" or cost-utility or "cost utility" or cost-benefit or "cost 
benefit" or "economic evaluation" or "cost per death" or "cost per case" or "cost per infection" or "cost per life" or "cost per disability 
adjusted" or "cost per quality adjusted" or "cost per disability-adjusted" or "cost per quality-adjusted" or "cost per qaly" or "cost per 
daly" [Words]  
and  
2012 or 2013 or 2014 [Country, year publication]  
and  
not study and protocol [Title words] 
ADOLEC 
(Bireme/WHO/PAH
O) 
cost-effective or "cost effective" or cost-effectiveness or "cost effectiveness" or cost-utility or "cost utility" or cost-benefit or "cost 
benefit" or "economic evaluation" or "cost per death" or "cost per case" or "cost per infection" or "cost per life" or "cost per disability 
adjusted" or "cost per quality adjusted" or "cost per disability-adjusted" or "cost per quality-adjusted" or "cost per qaly" or "cost per 
daly" [Words]  
and  
2012 or 2013 or 2014 [Country, year publication]  
and not  
study and protocol [Title words] 
Medline (including 
in-process) (Ovid 
SP) 
1. ("2012" or "2013" or "2014").yr. 
2. (cost-effectiveness or cost-utility or cost-benefit or "economic evaluation").ti,ab,kw. 
3. cost-effective.ti. 
4. ("cost-per-death-av*" or "cost-per-case-av*" or "cost-per-infection" or "cost-per-life" or "cost-per-disability-adjusted-life-year" or 
"cost-per-quality-adjusted-life-year" or "cost-per-qaly" or "cost-per-daly").ti,ab,kw. 
5. 2 or 3 or 4 
6. 1 and 5 
7. limit 6 to (autobiography or bibliography or biography or case reports or classical article or comment or congresses or consensus 
development conference or consensus development conference, nih or editorial or festschrift or guideline or historical article or in vitro 
or interactive tutorial or interview or lectures or letter or news or newspaper article or patient education handout or practice guideline 
or published erratum or technical report or twin study or video-audio media or webcasts) 
8. 6 not 7 
9. limit 8 to animals 
10. limit 9 to human 
11. 9 not 10 
12. 8 not 11 
13. study protocol.ti. 
14. 12 not 13 
Embase (Ovid SP) 1. ("2012" or "2013" or "2014").yr. 
2. (cost-effectiveness or cost-utility or cost-benefit or "economic evaluation").ti,ab,kw. 
3. cost-effective.ti. 
4. ("cost-per-death-av*" or "cost-per-case-av*" or "cost-per-infection" or "cost-per-life" or "cost-per-disability-adjusted-life-year" or 
"cost-per-quality-adjusted-life-year" or "cost-per-qaly" or "cost-per-daly").ti,ab,kw. 
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5. 2 or 3 or 4 
6. 1 and 5 
7. limit 6 to (book or book series or conference abstract or conference paper or conference proceeding or "conference review" or 
editorial or erratum or letter or note or report) 
8. 6 not 7 
9. limit 8 to (animals or animal studies) 
10. limit 9 to humans 
11. 9 not 10 
12. 8 not 11 
13. study protocol.ti. 
14. 12 not 13 
EconLit (Ovid SP) 1. ("2012" or "2013" or "2014").yr. 
2. health.af. 
3. (cost-effective* or cost-utility or cost-benefit or "economic evaluation").af. 
4. ("cost-per-death-av*" or "cost-per-case-av*" or "cost-per-infection" or "cost-per-life" or "cost-per-disability-adjusted-life-year" or 
"cost-per-quality-adjusted-life-year" or "cost-per-qaly" or "cost-per-daly").af. 
5. 3 or 4 
6. 1 and 2 and 5 
7. study protocol.ti. 
8. limit 6 to (books or book reviews or collective volume articles or dissertations) 
9. 6 not 8 
10. limit 9 to working papers 
11. 9 not 10 
PsycInfo(Ovid SP) 1. ("2012" or "2013" or "2014").yr. 
2. (cost-effectiveness or cost-utility or cost-benefit or "economic evaluation").mp. [mp=title, abstract, heading word, table of contents, 
key concepts, original title, tests & measures] 
3. cost-effective.ti. 
4. ("cost-per-death-av*" or "cost-per-case-av*" or "cost-per-infection" or "cost-per-life" or "cost-per-disability-adjusted-life-year" or 
"cost-per-quality-adjusted-life-year" or "cost-per-qaly" or "cost-per-daly").ti,ab,kw. 
5. 2 or 3 or 4 
6. 1 and 5 
7. limit 6 to ("0200 book" or "0240 authored book" or "0280 edited book" or "0300 encyclopedia" or "0400 dissertation abstract" or 
"column/opinion" or "comment/reply" or dissertation or editorial or encyclopedia entry or "erratum/correction" or letter or obituary) 
8. 6 not 7 
9. limit 8 to animal 
10. limit 9 to human 
11. 9 not 10 
12. 8 not 11 
13. study protocol.ti. 
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14. 12 not 13 
Global Health (Ovid 
SP) 
1. ("2012" or "2013" or "2014").yr. 
2. (cost-effectiveness or cost-utility or cost-benefit or "economic evaluation").af. 
3. cost-effective.ti. 
4. ("cost-per-death-av*" or "cost-per-case-av*" or "cost-per-infection" or "cost-per-life" or "cost-per-disability-adjusted-life-year" or 
"cost-per-quality-adjusted-life-year" or "cost-per-qaly" or "cost-per-daly").af. 
5. 2 or 3 or 4 
6. 1 and 5 
7. limit 6 to (annual report or annual report section or book or book chapter or bulletin or conference or conference proceedings or 
conference paper or correspondence or editorial or patent or thesis) 
8. 6 not 7 
9. study protocol.ti. 
10. 8 not 9 
Scopus (Scopus) MAIN SEARCH: 
((((TITLE("cost-effective*" OR "cost-utility" OR "cost-benefit" OR "economic evaluation") AND SUBJAREA(mult OR agri OR bioc OR 
immu OR neur OR phar OR mult OR medi OR nurs OR vete OR dent OR heal OR mult OR arts OR busi OR deci OR econ OR psyc 
OR soci) AND PUBYEAR > 2011) OR (TITLE("cost per death" OR "cost per case" OR "cost per infection" OR "cost per life" OR "cost 
per disability-adjusted" OR "cost per quality-adjusted" OR "cost per qaly" OR "cost per daly") AND SUBJAREA(mult OR agri OR bioc 
OR immu OR neur OR phar OR mult OR medi OR nurs OR vete OR dent OR heal OR mult OR arts OR busi OR deci OR econ OR 
psyc OR soci) AND PUBYEAR > 2011) OR (ABS("cost-effectiveness" OR "cost-utility" OR "cost-benefit" OR "economic evaluation") 
AND SUBJAREA(mult OR agri OR bioc OR immu OR neur OR phar OR mult OR medi OR nurs OR vete OR dent OR heal OR mult 
OR arts OR busi OR deci OR econ OR psyc OR soci) AND PUBYEAR > 2011) OR (ABS("cost per death" OR "cost per case" OR 
"cost per infection" OR "cost per life" OR "cost per disability-adjusted" OR "cost per quality-adjusted" OR "cost per qaly" OR "cost per 
daly") AND SUBJAREA(mult OR agri OR bioc OR immu OR neur OR phar OR mult OR medi OR nurs OR vete OR dent OR heal OR 
mult OR arts OR busi OR deci OR econ OR psyc OR soci) AND PUBYEAR > 2011) OR (AUTHKEY("cost-effectiveness" OR "cost-
utility" OR "cost-benefit" OR "economic evaluation") AND SUBJAREA(mult OR agri OR bioc OR immu OR neur OR phar OR mult OR 
medi OR nurs OR vete OR dent OR heal OR mult OR arts OR busi OR deci OR econ OR psyc OR soci) AND PUBYEAR > 2011)) 
AND (SUBJAREA(mult OR immu OR neur OR phar OR mult OR medi OR nurs OR dent OR heal OR deci OR econ OR psyc))) AND 
NOT (TITLE("study protocol"))) AND NOT (DOCTYPE(bk OR ch OR bz OR cp OR cr OR ed OR er OR le OR no OR pr OR rp OR 
sh)) 
 
BREAKING UP THE SEARCH: 
BY YEAR: 2014 – 1,216 
 
BY YEAR: 2013 – 4,039 
Broke this one up further – by “cost-effectiveness” in title, abstract, and keywords (3,148) and not (891) 
BY YEAR: 2012 – 3,751 
Social Science 
Citation Index & 
# 1 4,006,203 PY=(2012 or 2013 or 2014) 
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Science Citation 
Index extended 
(Web of Science) 
# 2 5,706 TI=("cost-effective*" or "cost-benefit" or "cost-utility" or "economic evaluation" or "cost per death" or "cost per case" or 
"cost per infection" or "cost per life" or "cost per disability-adjusted" or "cost per quality-adjusted" or "cost per qaly" or "cost per daly") 
# 3 13,274 TS=("cost-effectiveness" or "cost-benefit" or "cost-utility" or "economic evaluation" or "cost per death" or "cost per 
case" or "cost per infection" or "cost per life" or "cost per disability-adjusted" or "cost per quality-adjusted" or "cost per qaly" or "cost 
per daly") 
# 4 1,091 TITLE: ("study protocol") 
# 5 14,237 #3 OR #2 
# 6 14,237 #5 AND #1 
# 7 14,054 #6 not #4 
# 8 2,900 (#7) AND DOCUMENT TYPES: (Abstract of Published Item OR Art Exhibit Review OR Bibliography OR Biographical-
Item OR Book OR Book Chapter OR Book Review OR Chronology OR Correction OR Correction, Addition OR Dance Performance 
Review OR Database Review OR Discussion OR Editorial Material OR Excerpt OR Fiction, Creative Prose OR Film Review OR 
Hardware Review OR Item About an Individual OR Letter OR Meeting Abstract OR Meeting Summary OR Music Performance 
Review OR Music Score OR Music Score Review OR News Item OR Note OR Poetry OR Proceedings Paper OR Record Review OR 
Reprint OR Script OR Software Review OR TV Review, Radio Review OR TV Review, Radio Review, Video OR Theater Review) 
# 9 11,154 #7 NOT #8 
# 10 8,738 #9 AND WC=( PATHOLOGY OR BEHAVIORAL SCIENCES OR MEDICAL LABORATORY TECHNOLOGY OR 
BIOLOGY OR SOCIAL SCIENCES INTERDISCIPLINARY OR SOCIAL WORK OR HEALTH CARE SCIENCES SERVICES OR 
VIROLOGY OR MEDICINE GENERAL INTERNAL OR HEALTH POLICY SERVICES OR PUBLIC ENVIRONMENTAL 
OCCUPATIONAL HEALTH SCI OR PUBLIC ENVIRONMENTAL OCCUPATIONAL HEALTH OR MICROBIOLOGY OR 
PHARMACOLOGY PHARMACY OR RHEUMATOLOGY OR SOCIAL SCIENCES BM OR ECONOMICS OR NEUROSCIENCES OR 
PARASITOLOGY OR SURGERY OR ONCOLOGY OR REHABILITATION OR DENTISTRY ORAL SURGERY MEDICINE OR 
OPERATIONS RESEARCH MANAGEMENT SCIENCE OR FOOD SCIENCE TECHNOLOGY OR PUBLIC ENVIRONMENTAL 
OCCUPATIONAL HEALTH SSCI OR CARDIAC CARDIOVASCULAR SYSTEMS OR CRITICAL CARE MEDICINE OR INFECTIOUS 
DISEASES OR NURSING OR IMMUNOLOGY OR OPHTHALMOLOGY OR ANESTHESIOLOGY OR CLINICAL NEUROLOGY OR 
EMERGENCY MEDICINE OR MULTIDISCIPLINARY SCIENCES OR NUTRITION DIETETICS OR TOXICOLOGY OR MEDICINE 
RESEARCH EXPERIMENTAL OR SUBSTANCE ABUSE OR PSYCHIATRY OR DERMATOLOGY OR GASTROENTEROLOGY 
HEPATOLOGY OR GENETICS HEREDITY OR TRANSPLANTATION OR OBSTETRICS GYNECOLOGY OR TROPICAL 
MEDICINE OR MEDICAL INFORMATICS OR GERIATRICS GERONTOLOGY OR OTORHINOLARYNGOLOGY OR PERIPHERAL 
VASCULAR DISEASE OR ORTHOPEDICS OR MANAGEMENT OR PEDIATRICS OR UROLOGY NEPHROLOGY OR 
PSYCHIATRY SCI OR RESPIRATORY SYSTEM OR ENDOCRINOLOGY METABOLISM OR RADIOLOGY NUCLEAR MEDICINE 
MEDICAL IMAGING OR PRIMARY HEALTH CARE OR ENGINEERING ENVIRONMENTAL OR HEMATOLOGY)  Indexes=SCI-
EXPANDED, SSCI Timespan=2012-2014 
Scielo (Web of 
Science) 
# 1 79,842 PY=(2012 or 2013 or 2014) 
# 2 98 TI= ("cost-effective*" or "cost-benefit" or "cost-utility" or "economic evaluation" or "cost per death" or "cost per case" 
or "cost per infection" or "cost per life" or "cost per disability-adjusted" or "cost per quality-adjusted" or "cost per qaly" or "cost per 
daly") 
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# 3 221 TS=("cost-effectiveness" or "cost-benefit" or "cost-utility" or "economic evaluation" or "cost per death" or "cost per 
case" or "cost per infection" or "cost per life" or "cost per disability-adjusted" or "cost per quality-adjusted" or "cost per qaly" or "cost 
per daly") 
# 4 227 #2 or #3 
# 5 2 TI=("study protocol") 
# 6 227 #4 not #5 
# 7 175 #6 AND SU=( PUBLIC ENVIRONMENTAL OCCUPATIONAL HEALTH OR LEGAL MEDICINE OR GENERAL 
INTERNAL MEDICINE OR PEDIATRICS OR CARDIOVASCULAR SYSTEM CARDIOLOGY OR DENTISTRY ORAL SURGERY 
MEDICINE OR ANESTHESIOLOGY OR DERMATOLOGY OR PHARMACOLOGY PHARMACY OR ENDOCRINOLOGY 
METABOLISM OR GASTROENTEROLOGY HEPATOLOGY OR ENVIRONMENTAL SCIENCES ECOLOGY OR HEALTH CARE 
SCIENCES SERVICES OR NURSING OR MEDICAL LABORATORY TECHNOLOGY OR NEUROSCIENCES NEUROLOGY OR 
OPERATIONS RESEARCH MANAGEMENT SCIENCE OR OTORHINOLARYNGOLOGY OR OBSTETRICS GYNECOLOGY OR 
OPHTHALMOLOGY OR PSYCHIATRY OR PATHOLOGY OR RESPIRATORY SYSTEM OR RADIOLOGY NUCLEAR MEDICINE 
MEDICAL IMAGING OR TROPICAL MEDICINE OR SURGERY OR RHEUMATOLOGY OR UROLOGY NEPHROLOGY OR 
BIOTECHNOLOGY APPLIED MICROBIOLOGY OR INFECTIOUS DISEASES OR EConomics) 
# 8 13 (#7) AND DOCUMENT TYPES: (Announcement OR Article-Commentary OR Case-Report OR Editorial OR Letter 
OR Rapid-Communication) 
# 9 162 #7 not #8 
Biosis (Web of 
Science) 
# 1 1,608,659 PY=(2012 or 2013 or 2014) 
# 2 1,741 TI= ("cost-effective*" or "cost-benefit" or "cost-utility" or "economic evaluation" or "cost per death" or "cost per case" 
or "cost per infection" or "cost per life" or "cost per disability-adjusted" or "cost per quality-adjusted" or "cost per qaly" or "cost per 
daly") 
# 3 3,846 TS=("cost-effectiveness" or "cost-benefit" or "cost-utility" or "economic evaluation" or "cost per death" or "cost per 
case" or "cost per infection" or "cost per life" or "cost per disability-adjusted" or "cost per quality-adjusted" or "cost per qaly" or "cost 
per daly") 
# 4 4,109 #2 or #3 
# 5 4,109 #1 and #4 
# 6 35 TI= ("study protocol") 
# 7 4,104 #5 not #6 
# 8 777 (#7) AND DOCUMENT TYPES: (Annual Report OR Article Thesis Dissertation OR Book OR Book Chapter OR Book 
Review OR Company Profile OR Index OR Letter OR Main Cite OR Meeting OR Meeting Paper OR Obituary OR Patent OR Reprint 
OR Software OR Technical Report OR Thesis Dissertation) 
# 9 3,327 #7 NOT #8 
# 10 123 (#9) AND LITERATURE TYPE: (Annual Report OR Bibliography OR Biography OR Catalog OR Checklist OR 
Correction OR Dictionary OR Editorial OR Errata OR Identification Guide OR Manual OR Meeting Abstract OR Meeting Address OR 
Meeting Paper OR Meeting Poster OR Meeting Report OR Meeting Slide OR Meeting Summary OR Nomenclator OR Nomenclature 
OR Obituary OR Protocol OR Retraction OR Software Review OR Standard OR Taxonomic Key OR Taxonomic Review) 
# 11 3,204 #9 not #10 
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# 12 2,643 #11 AND SU=( TOXICOLOGY OR RADIOLOGY NUCLEAR MEDICINE MEDICAL IMAGING OR REPRODUCTIVE 
BIOLOGY OR HEMATOLOGY OR ANESTHESIOLOGY OR DEVELOPMENTAL BIOLOGY OR INFECTIOUS DISEASES OR 
ORTHOPEDICS OR PUBLIC ENVIRONMENTAL OCCUPATIONAL HEALTH OR BEHAVIORAL SCIENCES OR EVOLUTIONARY 
BIOLOGY OR IMMUNOLOGY OR REHABILITATION OR ONCOLOGY OR NURSING OR PHYSIOLOGY OR CARDIOVASCULAR 
SYSTEM CARDIOLOGY OR NUTRITION DIETETICS OR DENTISTRY ORAL SURGERY MEDICINE OR NEUROSCIENCES 
NEUROLOGY OR ALLERGY OR SURGERY OR OPHTHALMOLOGY OR GENETICS HEREDITY OR OBSTETRICS 
GYNECOLOGY OR GASTROENTEROLOGY HEPATOLOGY OR DERMATOLOGY OR GENERAL INTERNAL MEDICINE OR 
PARASITOLOGY OR HEALTH CARE SCIENCES SERVICES OR PSYCHIATRY OR PEDIATRICS OR GERIATRICS 
GERONTOLOGY OR ENDOCRINOLOGY METABOLISM OR RHEUMATOLOGY OR UROLOGY NEPHROLOGY OR 
RESPIRATORY SYSTEM OR OTORHINOLARYNGOLOGY ) 
Cinahl (EBSCO) S1. TI ("cost-effective*" or "cost-benefit" or "cost-utility" or "economic evaluation" or "cost per death" or "cost per case" or "cost per 
infection" or "cost per life" or "cost per disability-adjusted" or "cost per quality-adjusted" or "cost per qaly" or "cost per daly") 
S2. AB ("cost-effectiveness" or "cost-benefit" or "cost-utility" or "economic evaluation" or "cost per death" or "cost per case" or "cost 
per infection" or "cost per life" or "cost per disability-adjusted" or "cost per quality-adjusted" or "cost per qaly" or "cost per daly") 
S3. S1 OR S2 
S4. TI ("study protocol") 
S5. S3 NOT S4 
S6. S5 and PT (Algorithm OR Anecdote OR Bibliography OR Biography OR Book OR Book Chapter OR Book Review OR Brief Item 
OR Care Plan OR Cartoon OR Case Study OR CEU OR Classification Term OR Code of Ethics OR Commentary OR Computer 
Program OR Consumer/Patient Teaching Materials OR Critical Path OR Directories OR Doctoral Dissertation OR Editorial OR 
Evidence-Based Care Sheet OR Exam Questions OR Forms OR Games OR Glossary OR Historical Material OR Interview OR Legal 
Case OR Letter OR Masters Thesis OR Nurse Practice Acts OR Obituary OR Pamphlet OR Pamphlet Chapter OR Periodical OR 
Poetry OR Practice Acts OR Proceedings OR Quick Lesson OR Research Instrument Validation OR Response OR Standards OR 
Statistics OR Teaching Materials OR Tracings OR Trade Publication OR Website) 
S7. S5 NOT S6 
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Appendix 3 A note on database indexing terms 
In developing our search strategy, we explored the use of controlled vocabulary indexing terms, if 
available, in each of the databases; unlike author-defined keywords, these terms are generally 
applied to publications by professional indexers from a pre-defined set. While this standardization 
should offer advantages, one drawback is the delays in their application; while many of the 
databases offer basic citation data as supplied by the journal first, indexing takes more time and so 
searches based exclusively on indexing terms will exclude the most recent literature, to which index 
terms have not yet been applied.  
In Medline and Embase, indexing terms are known as medical subject headings (MeSH) and Emtree 
(which is not an acronym), respectively; both are organized hierarchically. While the only MeSH term 
relevant to our search is “cost-benefit analysis”, Emtree appears much more detailed and 
appropriate, as it distinguishes “cost effectiveness analysis”, “cost utility analysis”, and “cost benefit 
analysis” from “cost control”, “cost minimization analysis”, and “cost of illness” within the broader 
indexing term “economic evaluation.” When we compared the results of our searches in the title, 
abstract, and author-defined keywords for the key terms we identified above with the results of 
searches using MeSH terms (in Medline) and Emtree terms (in Embase), we found that the 
controlled vocabulary terms were both less specific and less sensitive. Our search terms identified 
many relevant articles missed by the MeSH and Emtree indexers. By contrast, the controlled 
vocabulary terms greatly increased the number of search results, but a review of the first hundred 
records identified by the MeSH term and, separately, by each of the three Emtree terms (i.e. 400 
records in total) after excluding records identified by our search terms identified only one additional 
article meeting our inclusion criteria (identified by the Emtree term “cost-effectiveness analysis” ). 
We used this article to develop an additional set of search terms (based on “cost per x”) and 
concluded that the MeSH and Emtree BM indexing terms were not useful for our final searches, as 
they identified a vast number of articles, many of which contained no cost or other economic data or 
analysis , while omitting many relevant publications  .  
Another database applying its own indexing is HEED . On the “compound search” page, HEED offers 
“type of econ eval” as a search category, as well as a “type of article”. While the associated picklist 
does not make this obvious, HEED in fact categorizes economic evaluations as “cost effectiveness 
analysis”, “cost utility analysis”, “cost benefit analysis”, “cost analysis”, “cost of illness”, “cost benefit 
analysis”,  and “cost consequences analysis”; it allows a single record to be classified as multiple 
types of economic evaluation, allows the user to specify only “applied study” as the “type of article”, 
and reports that its indexers are professional health economists. After examining this classification, 
we found that the terms for CEA, CUA, and CBA were highly specific and useful when combined with 
“applied study” as type of study , however, many publications in the HEED database were not 
classified at all, making the search relatively insensitive even within the HEED database. In HEED, we 
therefore implemented two separate searches: 1) using the HEED classification of the type of 
economic evaluation, and 2) using our search terms in the title, abstract, and author-defined 
keywords, and excluding records containing the specified categories, such that any records identified 
by this search would be additional to records identified by the use of HEED’s indexing.  
The EconLit  database uses the Journal of Economic Literature (JEL) classification system, however, 
unlike the indexing systems previously described, JEL codes are applied by the authors themselves. 
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They break down the wider health economics field into 6 specified sub-fields, none of which 
mention in their descriptions or examples either applied or methodological work in economic 
evaluation;  “general” and “other” health economics categories are also provided. On reviewing a 
selection of health economic evaluations in the EconLit database identified by title and abstract 
searches, we found that while some authors combine the codes “D61: Allocative Efficiency; Cost-
benefit analysis” (within the microeconomics heading) and “I12: Health Production” (within the 
health economics heading), other authors did not use these codes at all, choosing instead a wide 
variety of other codes within the health, microeconomics, and “miscellaneous” headings in 
particular, as well as others. Rather than using the JEL codes, we therefore decided to take a more 
sensitive approach in EconLit, and instead searched for “health” in all fields, which would capture 
the word “health” in JEL codes, but also in journal title, keywords, article title, or abstract; we 
combined this with keyword searches for our definition of economic evaluation. 
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Appendix 4 Mapping of 25 disease areas onto the Global Burden of Disease (GBD), International Classification of Disease (ICD-10), and search terms used 
Health areas developed for this analysis are listed in alphabetical order in the lefthand column. We mapped each component of the Global Burden of Disease (World Health 
Organization., 2014) onto one health area. The mapping of the ICD-10 codes (World Health Organization., 2011) onto GBD codes is taken from the GBD appendices. Both 
GBD and ICD-10 definitions were used to inform the development of search terms for each health areas, which were applied as necessary to the titles, abstracts, and/or 
keywords in the final database of economic evaluations. Underscores (“_”) have been used here to show single spaces and question marks (“?”) reflect a single wildcard 
character. GBD: Global Burden of Disease. ICD-10: International Classification of Disease, version 10.  
Health area GBD ICD-10 Search terms used to identify economic evaluations in this area 
Anaemia 58: Iron-deficiency 
anaemia 
D50, D64.9  Anaemia, Anemia, Anemic, Anaemic, Iron?deficien, _iron_, iron?supplement, 
Cancer and 
other 
neoplasms 
61: Malignant 
neoplasms, 79: 
Other neoplasms 
C00-C97, D00-D48 Adenocarcinoma, Adenoma, Cancer, carcinoma, chemoradiotherapy, 
Chemotherapy, Glioblastoma, glioma, Neoplasm, Radiation_therapy, 
Radiotherapy, Melanoma, Lymphoma, myeloma, neoplastic, Leukaemia, 
microcalcification, neoplasia, myelodysplas, leukemia, metastatic, sarcoma, 
paclitaxel, Hematopoietic_Stem_Cell, autologous_stem_cell, cervical_screen, 
pap_smear, lynch_syndrome, tumour, tumor, breast_reconstruction, 
metastasis, 
Cardiovascular 
diseases 
110: Cardiovascular 
diseases 
I00-I99 Angina, Angioplasty, Anticoagulants, aorta, aortic, Arrhythmia, Arrhythmic, 
arterial, artery, Atrial_Fibrillation, blood_pressure, blood_vessel, cardiac, 
cardio, carotid, Chest, cholesterol, Coronary, Deep_Vein_Thrombosis, 
embolism, heart, hypertensi, myocarditis, endocarditis, Myocardial, pulmonary, 
stroke, aneurysm, circulatory, warfarin, rheumatic, varicose_vein, venous*ulcer, 
vascular_disease, 
Communicable 
childhood 
diseases 
12: Childhood-cluster 
diseases 
A33-A37, B05 chickenpox, Pertussis, Whooping_cough, Diphtheria, Measles, Tetanus, 
chicken_pox, rubella, immunization, 
Congenital 
anomalies 
140: Congenital 
anomalies 
Q00-Q99 chromosom, cleft_lip, Dwarfism, cystic_fibrosis, Neural_tube_defect, Cleft_lip, 
Congenital, cleft_palate, Down_Syndrome, Down's_Syndrome, 
Down's_Syndrome, disabilities, disabled_children, neural_tube, congenital, 
Tetralogy_of_Fallot, spina_bifida, trisomy, polydactyl, teratogenic, 
Diabetes 80: Diabetes mellitus E10-E14 Diabetes, glucose, diabetic, hyperglycemi, 
Diarrhoeal 
diseases  
11: Diarrhoeal 
diseases 
A00, A01, A03, A04, A06-
A09 
diarrhea, diarrhoea, rotavirus, cholera, typhoid, shigell, amoebiasis, amoeba, 
rotaviral, enteritis, norwalk, adenovir, escherichia_coli, campylobacter, 
clostridium_difficile, dysentery, giardia, cryptosporid, norovirus, 
Digestive 
diseases 
121: Digestive 
diseases 
K20-K92 celiac, cholera, coeliac, crohn, Digestive, gallbladder, gallstones, gall?stones, 
gastric, gastro, helicobacter, ileostomy, colitis, constipation, Appendectomy, 
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Health area GBD ICD-10 Search terms used to identify economic evaluations in this area 
appendicitis, hernia_, bowel_, Intestinal_Polyps, Peptic_ulcer, diverticulitis, 
Cholecystolithiasis, pancreatitis, Cholecystitis, liver_, biliary, duodenal, vomit, 
ileus, hepatic, inguinal_hernia, 
Endocrine, 
blood, and 
immune 
disorders (not 
diabetes or HIV) 
81: Endocrine, blood, 
immune disorders 
D55-D64 (minus D64.9), 
D65-D89, E03-E07, E15-
E34, E65-E88 
graves_disease, Hormones, hyperthyroidism, hypothyroidism, Goiter, Endocrin, 
Haemophilia, Adrenal, Allerg, Anaphylaxis, hemophilia, thyroid, hematological, 
neutropenia, Ischaemi, Ischemi, tonsil, thalassaemia, thalassemia, 
Thrombocytopenia, Fabry_disease, lysosomal, sickle_cell, 
Genitourinary 
diseases, family 
planning & 
fertility 
126: Genitourinary 
diseases 
N00-N64, N75-N76, N80-
N98 
Gynecolog, Gynaecolog, contraception, contraceptive, embryo, fertility, 
fertilization, prostat, urologic, urinary, urethral_, genito, Kidney, Urolithiasis, 
nephrolog, Infertility, infertile, Nephrostomy, dialysis, pyelography, ovulation, 
urodynamic, ureter, hypogonadism, menstrual, nephropathy, microalbuminur, 
nephritis, bladder, varicocele, 
HIV/AIDS 10: HIV/AIDS B20-B24 Acquired_Immune_Deficiency_Syndrome, CD4, HAART, retroviral, hiv?aids, 
_hiv_, Human_Immunodeficiency_Virus, cd4_, 
Malaria 22: Malaria B50-B54, P37.3, P37.4 bed?net, malaria, bednet, artemesenin, 
Malnutrition 
(including 
obesity and 
exercise) 
54: Nutritional 
deficiencies (except 
58: Iron-deficiency 
anaemia) 
E00-E02, E40-E46, E50-
E64, D51-D53 
bariatric, Body_Mass_Index, Body_Weight, nutrition, Iodine, Vitamin_A, 
obesity, obese, physical_activity, exercise, pedometer, vegetable, dietary, 
biofortif, weight_management, 
Maternal and 
neonatal 
conditions 
42: Maternal 
conditions, 49: 
Neonatal conditions 
O00-O99, P00-P96 excl 
P37.3, P37.4  
low?birth?weight, Preterm, Birth, Neonat, Newborn, New-born, Amniocentesis, 
Birth, caesarean, cesarean, fetal, folic_acid, gestational, preeclampsia, 
eclampsia, pregnancy, prenatal, abortion, endometrial, obstetric, 
premature_infant, prematurity, vaginal_deliver, 
Meningitis  17: Meningitis A39, G00, G03 mening, 
Mental health, 
cognition, and 
developmental 
and behavioural 
disorders 
(including self-
harm and 
addictions) 
82: Mental and 
behavioural 
disorders, 161: Self-
harm 
F04-F99, X41-X42, X45, 
X60-X84, Y870 
  
ADHD, Agoraphobi, Antidepressant, Antidepressive, Anxiety, autism, Autistic, 
Schizophreni, Bipolar, _cognition, cognitive, Dementia, depression, 
substance_use_disorder, opiate_substitution, Eating_Disorder, _Emotions, 
mental_health, heroin, psychosis, psychotic, Unipolar, cocaine, addiction, 
Alcohol_use, Drug_use, developmental_disorder, behavioural_disorder, 
intellectual, behavio?r_disorder, clinically_isolated_syndrome, mentally_ill, 
Somatoform, depressive_disorder, Alcohol, Drug_Abuse, Drug_Addiction, 
Narcotic_Control, smoking, substance_abuse, Psychotherapy, mental_illness, 
Mental_Disorder, suicide, smoker, methadone, methadone, delirium, Nicotine, 
attention?deficit?hyperactivity?disorder, fear_of, behavior_disorder, cannabis, 
Musculoskeletal 
diseases 
134: Musculoskeletal 
diseases 
M00-M99 ankle, Bone, Carpal_Tunnel, Cartilage, elbow, fracture, Joint, knee, Ligament, 
arthritis, Lumbar, Diskectomy, discectomy, musculoskeletal, 
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Health area GBD ICD-10 Search terms used to identify economic evaluations in this area 
(including back 
and neck pain) 
Physical_Therapy_, osteoporo, fibromyalgia, Spinal, foot, shoulder, orthopedic, 
hip_replacement, lupus, Gout, low?back_pain, 
Neurological 
conditions 
(including 
headache and 
sleep disorders) 
94: Neurological 
conditions 
F01-F03, G06 -G98 cerebral, nervous_system, neurological, Epilepsy, Alzheimer, Parkinson, 
Epileptic, Multiple_sclerosis, Migraine, headache, sleep, Myasthenia_gravis, 
thymectomy, neurosurgery, neuropath, chronic_fatigue_syndrome, neuralgia, 
Other infectious 
diseases 
(including 
encephalitis, 
hep A, B, C, and 
other parasitic 
and vector-
borne diseases, 
and nematode 
infections) 
18: Encephalitis, 19: 
Acute hepatitis B, 20: 
Acute hepatitis C, 
21: Parasitic and 
vector diseases 
(except 22: Malaria), 
33: Intestinal 
nematode infections, 
37: Other infectious 
diseases 
A83-A86, B94.1, G04, B16-
B19 (minus B17.1, B18.2), 
B17.1, B18.2, A30, A71, 
A82, A90-A91, B55-B57, 
B65, B73, B74.0-B74.2, 
B76-B77, B79, A02, A05, 
A20-A28, A31, A32, A38, 
A40-A49, A65-A70, A74-
A79, A80-A81, A87-A89, 
A92-A99, B00-B04, B06-
B15, B25-B49, B58-B60, 
B64, B66-B72, B74.3-B74.9, 
B75,B78, B80-B89, B91- 
B99 (minus B94.1) 
Encephaliti, Dengue, lyme_, deworming, hepatitis, hep_b, hep_c, 
Trypanosomiasis, Chagas, Schistosom, Leishmania, Lymphatic_filariasis, 
Onchocerciasis, Leprosy, leprous, Trachoma, Rabies, Ascariasis, Trichuriasis, 
Hookworm, hep_a, rubella, herpes_zoster, clostridium, Staphylococc, 
Bacteremia, hospital-acquired_infection, septic_shock, sepsis, Staphylococc, 
scabies, systemic_Candida_infection, cytomegalovirus, infection_control, hcv, 
Creutzfeldt?Jakob, _invasive_Candid, Helminth, roundworm, antimicrobial, 
Respiratory 
diseases 
38: Respiratory 
infections, 117: 
Respiratory diseases 
J00-J22, H65-H68,P23, 
U04, J30-J98 
Respiratory, Pulmonary, Lung, Bronchial, Trachea, Bronchitis, Airway, Asthma, 
H1N1, Influenza, bird_flu, avian_flu,  interstit, Pleural_effusion, sore_throat, 
pneumonia, Respiration, pneumococcal, Haemophilus, breathing, pharyngitis, 
pneumonia, 
Sense organ 
diseases 
102: Sense organ 
diseases 
H00-H61, H69-H93  Blindness, Cataract, cochlear, deafness, eye_, Glaucoma, hearing, Macular, 
rhino, Nasolacrimal, Refractive_error, vision_loss, hearing_loss, canaloplasty, 
Trabeculectomy, retina, Ophthalmolog, keratoplasty, otitis_media, 
Skin and oral 
conditions 
133: Skin diseases, 
147: Oral conditions 
L00-L98, K00-K14  debridement, Dental, Dentistry, Denture, gingival, Edentulism, Periodontal, 
peritonsillar, Dentition, Orthodontics, Dermatitis, Dermatolog, Eczema, 
skin_disease, tinea, psoriasis, dermatophytic, plantar_wart, skin?graft, 
soft_tissue, foam_dressing, pressure_ulcer, 
Sexually 
Transmitted 
Infections (not 
HIV) 
4: STDs excluding 
HIV 
A50-A64, N70-N73 chlamydia, condoms, Gonorrhea, Papillomavirus, Syphilis, Gonorrhoea, 
Trichomoniasis, Sexually_Transmitted, hpv, 
Tuberculosis 3: Tuberculosis A15-A19, B90 antitubercular, BCG, TB, tuberculos, bacille_Calmette-Guerin, 
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Health area GBD ICD-10 Search terms used to identify economic evaluations in this area 
Wounds and 
injuries 
151: Injuries (except 
161: Self-harm) 
V01-X59, Y871-Y89,  Injury, Injuries, Accident, Burn, violence, Poisoning, Drown, child_abuse, 
domestic_abuse, Domestic_Violence, trauma, fall_prevention, falls_prevention, 
venom, antidote, whiplash, _radon_, road_safety, 
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Appendix 5 Supplementary information on article classification 
Health areas  
We developed a classification of 25 health areas so as to allow comparability with the Global Burden 
of Disease (GBD) estimates (World Health Organization., 2014), to be implementable with an 
electronic key term search, and to permit meaningful analysis. The GBD uses four hierarchical levels 
to classify disease. At its highest level, it classifies diseases as “Communicable, maternal, perinatal 
and nutritional conditions”, “Non-communicable diseases” or “Injuries”, while at its lowest levels, it 
breaks these down into 154 more specific conditions. We did not maintain the GBD’s highest level 
classification because in some cases, it was not implementable (e.g. key term searches could not 
distinguish between communicable and non-communicable causes of respiratory diseases) and in 
other cases, we felt the distinction did not map coherently onto preventive and curative 
interventions (e.g. we separated “intentional injuries: self harm” from other injury categories and 
placed it in a single category with mental health issues).  
A set of up to 49 search terms was developed for each of our health areas through an iterative 
process. We began by reviewing the names of sub-categories in the GBD and the categories and 
descriptions provided in the ICD-10 (World Health Organization., 2011) to develop an initial set of 
search terms. We then reviewed the titles and keywords of unclassified records in our database, and 
continued adding search terms until all records in our database which could be classified were 
classified according to at least one health area. Throughout the process, we reviewed samples of 
records within each health area, and reviewed in-depth the records identified by search terms we 
considered potentially ambiguous, before finalizing our search terms and disease classification.  
Institutional and geographic affiliations of authors 
We analyzed data on the institutional affiliation of all authors to develop a comprehensive picture of 
the institutions and countries contributing to health economic evaluations. We began by transferring 
the institutional affiliation data from wide to long form and implementing the country keyword 
searches previously developed. As affiliation data frequently did not name a country, unclassified 
affiliations were then iteratively reviewed and search terms for city names and non-geographic 
institution names (e.g. Harvard, Yale) were identified and linked to countries, taking care to avoid 
misclassifying search terms such as “York”, which could refer to the city (York) or county (Yorkshire) 
in the United Kingdom, to York University in Canada, or to the city or state of New York in the United 
States. In this way, nearly all articles for which affiliation data were available were classified as being 
produced by researchers in one or more specified countries. This data was further cross-checked 
against the data on countries studied and inconsistencies reviewed. The original articles were sought 
to resolve inconsistencies and to obtain institutional affiliation data for any articles remaining 
without data. Articles were then classified by the income group of the country or countries of the 
author affiliations and the countries producing the greatest volume of economic evaluations were 
ranked within each income group.  
We further identified the top ten institutions within each income group by volume of economic 
evaluations produced. The affiliation data for top-ranked countries within each income group were 
carefully reviewed to develop sets of specific key terms for institutions. As in previous work 
(Wagstaff and Culyer, 2012, Rubin and Chang, 2003), schools, colleges and institutes were 
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aggregated with the university to which they belonged, with the exception of the highly federal 
Universities of London, California, Texas, and other similar university systems, whose constituent 
members were analyzed separately. To the extent possible, hospitals and institutes were associated 
with their parent institution, even when that institution was not explicitly named. Even though they 
are independently owned and managed, Harvard’s 16 affiliated hospitals were aggregated with 
Harvard. Once an initial set of ten institutions were identified for each income group, only affiliations 
from countries which had produced more than the tenth-ranked institution for that income group 
were reviewed to identify institutions which could have produced more economic evaluations than 
the currently tenth-ranked institution. For example, the tenth-ranked UMIC institution, the Instituto 
Mexicano del Seguro Social, produced 7 economic evaluations, and so only affiliations from UMICs 
which had produced at least 7 economic evaluations were reviewed to identify individual institutions 
which could have produced at least this number. The searches for city names were then used to 
facilitate the identification of institutions. 
In addition, search terms were developed for international and inter-governmental organizations, 
such as United Nations agencies and the World Bank, and for multi-national pharmaceutical 
companies, regardless of the country, if any, with which they were associated in their affiliation 
data. These were then aggregated into two groups, “international organizations” and 
“pharmaceutical industry”, to permit consideration of their relative influence. 
This process allowed a comprehensive assessment of the total volume of articles produced by each 
country and by income group, as well as a comprehensive assessment of top institutions, taking into 
account the many and unpredictable variations in their listing. Less thorough approaches would be 
likely to bias rankings towards institutions such as Yale, with its unique name which also appears in 
the name of all its constituent schools and hospital, and away from institutions with a wider variety 
of permutations, abbreviations and possibly ambiguous versions of its name, such as the University 
of York (Univ York, U York, but not York University), with Hull-York Hospital (Hull-York Hosp), which 
were not always listed with the university name in the affiliation data. 
We considered a number of possible approaches for analysing articles with more than one 
institutional affiliation. Both Wagstaff and Culyer (2012) and Rubin and Chang (2003) were 
constrained by the EconLit database, which only provides data on the first three or four authors, 
whereas we obtained institutional affiliation data for all authors. We considered assigning a 
fractional value (and even weighted fractional values reflecting author order) to each institution 
based on the number of different authors or institutions represented on a given article (Aksnes et 
al., 2012, Hagen, 2013, Retzer and Jurasinski, 2009). However, we rejected such approaches for two 
reasons: first, we believe that the use of zero-sum metrics establishes a perverse incentive against 
collaboration between institutions and against the crediting of collaborators. We therefore assigned 
one point per institution per article, regardless of the number of institutions or authors on a given 
article. This has the disadvantage of weighting the analysis towards articles from multiple 
institutions, as these articles are counted multiple times. 
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Appendix 6 Classification of journal types 
The following is a comprehensive list of how we classified journals publishing at least one economic evaluation 
meeting our criteria.  
Health economics, policy, and services journals  
Administration and Policy in Mental Health and 
Mental Health Services Research 
AIDS and behavior 
Alter 
American Health and Drug Benefits 
Applied Health Economics and Health Policy 
Behaviour research and therapy 
BMC HEALTH SERVICES RESEARCH 
BMC Medical Informatics and Decision Making 
British Journal of Health Care Management 
Bulletin of the World Health Organization 
Cancer Management and Research 
CHILDREN AND YOUTH SERVICES REVIEW 
ClinicoEconomics and Outcomes Research 
Cost Effectiveness and Resource Allocation 
Decision Sciences 
Epilepsy and Behavior 
European Journal of Health Economics 
European Review of Agricultural Economics 
Expert review of pharmacoeconomics and outcomes 
research 
Gesundheitsokonomie und Qualitatsmanagement 
GMS health technology assessment 
Health Affairs 
Health Economics 
Health Economics Review 
Health Policy 
Health Policy and Planning 
Health Policy and Technology 
Health Services Research 
Health Technology Assessment 
Healthcare Policy 
International Journal of Behavioral Nutrition and 
Physical Activity 
International Journal of Drug Policy 
International Journal of Technology Assessment in 
Health Care 
Israel Journal of Health Policy Research 
Journal d'Economie Medicale 
Journal of Benefit-Cost Analysis 
Journal of health economics 
JOURNAL OF HEALTH SERVICES RESEARCH and 
POLICY 
Journal of Medical Economics 
Journal of Mental Health Policy and Economics 
Journal of Nursing Management 
JOURNAL OF NUTRITION EDUCATION AND 
BEHAVIOR 
Journal of Pain and Symptom Management 
Journal of Pharmaceutical Health Services Research 
Journal of Public Health Management and Practice 
Medical Decision Making 
Mediterranean Journal of Social Sciences 
Ontario Health Technology Assessment Series 
Open Pharmacoeconomics and Health Economics 
Journal 
PharmacoEconomics 
PharmacoEconomics - Italian Research Articles 
Pharmacoeconomics - Spanish Research Articles 
Population Health Management 
Psychological Services 
Research in Social and Administrative Pharmacy 
Revista medica del Instituto Mexicano del Seguro 
Social 
Social Psychiatry and Psychiatric Epidemiology 
South African Journal of Economic and Management 
Sciences 
Substance abuse treatment, prevention, and policy 
Therapeutics and Clinical Risk Management 
Value in Health 
Value in Health Regional Issues 
Vascular Health and Risk Management 
Biomedical journals 
[Rinsho ketsueki] The Japanese journal of clinical 
hematology 
Academic Emergency Medicine 
Academic Pediatrics 
Acta Chirurgiae Orthopaedicae et Traumatologiae 
Cechoslovaca 
Acta Chirurgica Belgica 
Acta clinica Belgica 
Acta gastroenterologica Latinoamericana 
Acta Medica Indonesiana 
Acta neurochirurgica 
Acta Neurologica Scandinavica 
Iowa Orthopaedic Journal 
Iranian journal of neurology 
Iranian Journal of Pediatrics 
Iranian Journal of Pharmaceutical Research 
Iranian Journal of Radiology 
Iranian Red Crescent Medical Journal 
Irish Journal of Medical Science 
ISRN Gastroenterology 
ISRN Obstetrics and Gynecology 
Italian Journal of Public Health 
JACC: Heart Failure 
JAMA 
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Acta Neuropsychiatrica 
Acta Obstetricia et Gynecologica Scandinavica 
Acta Oncologica 
Acta Ophthalmologica 
Acta Oto-Laryngologica 
Acta Psychiatrica Scandinavica 
Acta Radiologica 
Actas dermo-sifiliograficas 
Actas Urologicas Espanolas 
Acupuncture in Medicine 
Addiction 
Advances in Clinical and Experimental Medicine 
Advances in Skin and Wound Care 
Advances in Therapy 
Aesthetic Surgery Journal 
African health sciences 
African Journal of AIDS Research 
African Journal of Urology 
Age and Ageing 
AIDS 
AIDS Care 
Alcohol and Alcoholism 
Alcoholism Clinical and Experimental Research 
Alimentary Pharmacology and Therapeutics 
Allergologie 
Alzheimer's and Dementia 
American heart journal 
American Journal of Cardiology 
American Journal of Cardiovascular Drugs 
American Journal of Clinical Dermatology 
American Journal of Clinical Oncology 
American Journal of Emergency Medicine 
American Journal of Gastroenterology 
American Journal of Geriatric Psychiatry 
American Journal of Health-System Pharmacy 
AMERICAN JOURNAL OF HYPERTENSION 
American Journal of Industrial Medicine 
American Journal of Infection Control 
American Journal of Kidney Diseases 
American Journal of Managed Care 
American Journal of Medical Genetics Part A 
American Journal of Medicine 
American Journal of Neuroradiology 
American Journal of Obstetrics and Gynecology 
American journal of ophthalmology 
American Journal of Perinatology 
American Journal of Pharmacy Benefits 
American Journal of Physical Medicine and 
Rehabilitation 
American Journal of Preventive Medicine 
American Journal of Public Health 
American Journal of Rhinology and Allergy 
American Journal of Roentgenology 
American Journal of Speech-Language Pathology 
American journal of sports medicine 
American Journal of Surgery 
AMERICAN JOURNAL OF THERAPEUTICS 
JAMA Ophthalmology 
JAMA Pediatrics 
Japanese Journal of Ophthalmology 
Japanese Pharmacology and Therapeutics 
Joint Commission Journal on Quality and Patient 
Safety 
Joint, Bone, Spine 
Jornal Portugues de Gastrenterologia 
Journal de Mycologie Medicale 
Journal for Healthcare Quality 
Journal of Acquired Immune Deficiency Syndromes 
Journal of Adolescent Health 
Journal of Advanced Nursing 
Journal of affective disorders 
Journal of Aging Research 
Journal of Allergy and Clinical Immunology 
Journal of Alternative and Complementary Medicine 
Journal of Antivirals and Antiretrovirals 
Journal of Anxiety Disorders 
Journal of Arthroplasty 
Journal of Arthropod-Borne Diseases 
Journal of Asthma 
Journal of bone and joint surgery 
Journal of Bone and Mineral Research 
Journal of Brain Science 
Journal of Bronchology and Interventional 
Pulmonology 
Journal of Burn Care and Research 
Journal of Cancer 
Journal of Cancer Epidemiology 
Journal of Cardiothoracic Surgery 
Journal of Cardiovascular Computed Tomography 
Journal of Cardiovascular Electrophysiology 
Journal of Cardiovascular Magnetic Resonance 
Journal of Cardiovascular Medicine 
Journal of Cardiovascular Nursing 
Journal of Cataract and Refractive Surgery 
Journal of Child and Adolescent Substance Abuse 
Journal of Child and Family Studies 
Journal of Children's Orthopaedics 
Journal of Clinical Apheresis 
Journal of Clinical Endocrinology and Metabolism 
Journal of clinical gastroenterology 
Journal of Clinical Hypertension 
Journal of clinical lipidology 
JOURNAL OF CLINICAL MICROBIOLOGY 
Journal of clinical nursing 
Journal of Clinical Oncology 
Journal of Clinical Periodontology 
Journal of Clinical Psychiatry 
Journal of Clinical Sleep Medicine 
Journal of Clinical Ultrasound 
Journal of Clinical Virology 
Journal of Cognitive and Behavioral Psychotherapies 
Journal of community health 
Journal of Comparative Effectiveness Research 
JOURNAL OF CROHNS and COLITIS 
  WORKING PAPER: Economic evaluation in global perspective Page A20 of A32 
 
American Journal of Transplantation 
American Journal of Tropical Medicine and Hygiene 
Anesthesiology 
Angiology 
Annali di igiene : medicina preventiva e di comunita 
Annals of Allergy, Asthma and Immunology 
Annals of cardiothoracic surgery 
Annals of Emergency Medicine 
Annals of General Psychiatry 
Annals of Hematology 
Annals of Internal Medicine 
Annals of Nuclear Medicine 
Annals of Oncology 
Annals of Pharmacotherapy 
Annals of Plastic Surgery 
Annals of rehabilitation medicine 
Annals of Surgery 
Annals of Surgical Oncology 
Annals of the Rheumatic Diseases 
Annals of the Royal College of Surgeons of England 
Annals of Thoracic Surgery 
Annals of Vascular Surgery 
Antimicrobial Agents and Chemotherapy 
Antiviral therapy 
ANZ Journal of Surgery 
Archives of Disease in Childhood 
Archives of Gynecology and Obstetrics 
Archives of Internal Medicine 
Archives of Iranian Medicine 
Archives of Medical Research 
Archives of Medical Science 
Archives of Ophthalmology 
Archives of Pathology and Laboratory Medicine 
Archives of Pediatrics and Adolescent Medicine 
Archives of Surgery 
ARCHIVOS DE BRONCONEUMOLOGIA 
Archivos de Neurociencias 
Arquivos brasileiros de cardiologia 
Arquivos Brasileiros de Oftalmologia 
Arquivos de Gastroenterologia 
Arthritis Care and Research 
Arthroscopy 
ARYA Atherosclerosis 
Asian Biomedicine 
Asian Pacific Journal of Cancer Prevention 
Asian Pacific Journal of Tropical Disease 
Asia-Pacific Journal of Clinical Oncology 
Asia-Pacific Journal of Public Health 
Atencion Farmaceutica 
Atencion Primaria 
Australian and New Zealand Journal of Obstetrics and 
Gynaecology 
Australian and New Zealand journal of public health 
Australian Health Review 
Australian Journal of Primary Health 
Autism 
Biochemia medica 
Journal of Crohn's and Colitis 
Journal of Cystic Fibrosis 
Journal of Dental Research 
Journal of Dermatological Treatment 
Journal of Endourology 
Journal of Endovascular Therapy 
JOURNAL OF EPIDEMIOLOGY AND COMMUNITY 
HEALTH 
Journal of evaluation in clinical practice 
Journal of Food and Drug Analysis 
Journal of Food Protection 
JOURNAL OF FOOT AND ANKLE RESEARCH 
JOURNAL OF GASTROENTEROLOGY AND 
HEPATOLOGY 
Journal of Gastrointestinal Cancer 
Journal of Gastrointestinal Surgery 
Journal of General Internal Medicine 
Journal of Global Health 
Journal of gynecologic oncology 
Journal of hand surgery 
journal of headache and pain 
Journal of Hearing Science 
Journal of Heart and Lung Transplantation 
JOURNAL OF HEPATOLOGY 
Journal of Hospital Infection 
Journal of Hospital Medicine 
Journal of Hypertension 
Journal of Infection 
Journal of Infectious Diseases 
Journal of Interventional Cardiology 
Journal of Korean Academy of Nursing Administration 
Journal of Korean Medical Science 
Journal of long-term effects of medical implants 
Journal of Lower Genital Tract Disease 
Journal of Managed Care Medicine 
Journal of Managed Care Pharmacy 
journal of maternal-fetal and neonatal medicine 
Journal of Medical Colleges of PLA 
Journal of Medical Internet Research 
Journal of Mental Health 
Journal of microbiology, immunology, and infection = 
Wei mian yu gan ran za zhi 
Journal of Nervous and Mental Disease 
Journal of Neurology 
Journal of Neurology Neurosurgery and Psychiatry 
Journal of Neuro-Ophthalmology 
Journal of neurosurgery 
Journal of neurosurgery. Spine 
Journal of Neurosurgery: Spine 
JOURNAL OF NEUROSURGERY-SPINE 
Journal of Nuclear Medicine 
Journal of Nursing Scholarship 
Journal of Nutrition 
JOURNAL OF OBSTETRICS AND GYNAECOLOGY 
Journal of Obstetrics and Gynaecology Canada 
Journal of Occupational and Environmental Medicine 
Journal of Occupational Rehabilitation 
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BioDrugs 
Biologics in Therapy 
Biology of Blood and Marrow Transplantation 
BioMed research international 
Biomedica 
BIOMEDICAL ENGINEERING-BIOMEDIZINISCHE 
TECHNIK 
Biomedical Journal 
Biosecurity and Bioterrorism 
BIOSYSTEMS 
BIOTECHNOLOGY and BIOTECHNOLOGICAL 
EQUIPMENT 
BJOG: An International Journal of Obstetrics and 
Gynaecology 
BJU International 
Blood purification 
BMC Anesthesiology 
BMC Cancer 
BMC Cardiovascular Disorders 
BMC Clinical Pharmacology 
BMC Complementary and Alternative Medicine 
BMC family practice 
BMC Gastroenterology 
BMC infectious diseases 
BMC Medical Research Methodology 
BMC Medicine 
BMC Musculoskeletal Disorders 
BMC Neurology 
BMC ophthalmology 
BMC Pediatrics 
BMC pregnancy and childbirth 
BMC Psychiatry 
BMC PUBLIC HEALTH 
BMC research notes 
BMJ 
BMJ Open 
BMJ quality and safety 
BMJ supportive and palliative care 
Boletin Medico del Hospital Infantil de Mexico 
Bone 
bone and joint journal 
Brachytherapy 
Brazilian Journal of Infectious Diseases 
Brazilian Journal of Pharmaceutical Sciences 
Breast Cancer Research and Treatment 
Breast Cancer: Targets and Therapy 
Breast Care 
Breastfeeding Medicine 
British Journal of Anaesthesia 
British Journal of Cancer 
British Journal of Dermatology 
British Journal of General Practice 
British Journal of Haematology 
British Journal of Ophthalmology 
British Journal of Psychiatry 
British Journal of Sports Medicine 
British Journal of Surgery 
Journal of Oncology Pharmacy Practice 
Journal of Oncology Practice 
Journal of Orthopaedic Research 
Journal of orthopaedic trauma 
Journal of Otolaryngology - Head and Neck Surgery 
Journal of Pain and Palliative Care Pharmacotherapy 
Journal of pediatric ophthalmology and strabismus 
Journal of Pediatrics 
Journal of Perinatology 
Journal of Periodontology 
Journal of Pharmacy Practice 
Journal of Plastic, Reconstructive and Aesthetic 
Surgery 
Journal of Population Therapeutics and Clinical 
Pharmacology 
Journal of Practical Oncology 
Journal of primary care and community health 
Journal of Psychiatric Research 
Journal of Psychosomatic Research 
Journal of Public Health 
JOURNAL OF PUBLIC HEALTH DENTISTRY 
Journal of Radiation Research 
Journal of Rehabilitation Medicine 
Journal of research in health sciences 
Journal of Sexual Medicine 
Journal of Shoulder and Elbow Surgery 
Journal of Spinal Disorders and Techniques 
Journal of Stroke and Cerebrovascular Diseases 
Journal of Studies on Alcohol and Drugs 
Journal of Substance Abuse Treatment 
Journal of Surgical Oncology 
Journal of Surgical Research 
Journal of Telemedicine and Telecare 
Journal of the Academy of Nutrition and Dietetics 
Journal of the American Academy of Audiology 
Journal of the American Academy of Dermatology 
Journal of the American College of Cardiology 
Journal of the American College of Surgeons 
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY 
Journal of the American Medical Directors 
Association 
Journal of the American Medical Informatics 
Association 
Journal of the American Pharmacists Association 
Journal of the American Society of Nephrology 
Journal of the Balkan Union of Oncology 
Journal of the European Academy of Dermatology 
and Venereology 
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION 
Journal of the International Association of Providers 
of AIDS Care 
Journal of the Medical Association of Thailand 
Journal of the National Cancer Institute 
Journal of the National Comprehensive Cancer 
Network 
Journal of the Neurological Sciences 
Journal of the Pakistan Medical Association 
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Bulletin du Cancer 
Cadernos de Saude Publica 
CADTH technology overviews 
Canadian Journal of Cardiology 
Canadian Journal of Infectious Diseases and Medical 
Microbiology 
Canadian Journal of Ophthalmology 
Canadian Journal of Surgery 
Canadian Journal of Urology 
Canadian Journal on Aging 
Canadian Medical Association Journal 
Canadian Urological Association Journal 
Cancer 
Cancer Causes and Control 
Cancer Epidemiology Biomarkers and Prevention 
Cancer Epidemiology, Biomarkers and Prevention 
Cancer Prevention Research 
Cardiogenetics 
CardioVascular and Interventional Radiology 
Cardiovascular Drugs and Therapy 
Cardiovascular journal of Africa 
Cardiovascular Therapeutics 
Caries Research 
Catheterization and Cardiovascular Interventions 
Cerebrovascular Diseases 
Ceska Gynekologie 
Chest 
Child and Adolescent Psychiatry and Mental Health 
Childhood Obesity 
Chinese Journal of Cancer Prevention and Treatment 
Chinese Journal of Clinical Nutrition 
Chinese Journal of Clinical Oncology 
Chinese Journal of Evidence-Based Medicine 
Chinese Journal of Lung Cancer 
Chinese Journal of New Drugs 
Chinese Journal of Oncology 
Chinese Journal of Schistosomiasis Control 
Chinese Journal of Tissue Engineering Research 
Chinese Pharmaceutical Journal 
Chinese Preventive Medicine 
Chongqing Medicine 
Ciencia and saude coletiva 
Ciencia y Enfermeria 
Circulation 
Circulation: Cardiovascular Quality and Outcomes 
Circulation: Heart Failure 
CIRCULATION-CARDIOVASCULAR QUALITY AND 
OUTCOMES 
Cirugia Espanola 
Cirugia y Cirujanos 
Clinica e Investigacion en Ginecologia y Obstetricia 
Clinical and Experimental Nephrology 
Clinical and experimental obstetrics and gynecology 
Clinical and Experimental Rheumatology 
Clinical and translational allergy 
Clinical Breast Cancer 
Clinical Cardiology 
Journal of the Royal Society Interface 
Journal of the Royal Society of Medicine 
Journal of Theoretical Biology 
Journal of Thoracic and Cardiovascular Surgery 
Journal of Thoracic Oncology 
Journal of Thrombosis and Haemostasis 
Journal of thrombosis and thrombolysis 
Journal of Traditional Chinese Medicine 
Journal of Trauma and Acute Care Surgery 
Journal of Urban Health 
Journal of Urology 
Journal of vascular and interventional neurology 
Journal of Vascular and Interventional Radiology 
Journal of Vascular Nursing 
Journal of Vascular Surgery 
JOURNAL OF VIRAL HEPATITIS 
Journal of Women's Health 
Journal of wound care 
Kardiologia Polska 
KARDIOLOGIYA 
Kidney and Blood Pressure Research 
Klimik Dergisi 
Klinische Monatsblatter fur Augenheilkunde 
Klinische P+ndiatrie 
Knee Surgery, Sports Traumatology, Arthroscopy 
Korean Journal of Thoracic and Cardiovascular 
Surgery 
La Radiologia medica 
Lancet 
Lancet Global Health 
Lancet Infectious Diseases 
Laryngoscope 
Leukemia and Lymphoma 
Lin chuang er bi yan hou tou jing wai ke za zhi = 
Journal of clinical otorhinolaryngology, head, and 
neck surgery 
Liver Transplantation 
Lung Cancer 
Malaria Journal 
Managed Care 
Maternal and Child Health Care of China 
Mathematical Biosciences and Engineering 
Medical Care 
MEDICAL HYPOTHESES 
MEDICAL JOURNAL OF AUSTRALIA 
Medical Journal of Chinese People's Liberation Army 
Medical Journal of Malaysia 
Medicina Preventiva 
Medicine, Health Care and Philosophy 
Methodist DeBakey cardiovascular journal 
Midwifery 
Modern Preventive Medicine 
Molecular and Clinical Oncology 
Molecular Diagnosis and Therapy 
MOVEMENT DISORDERS 
Multiple Sclerosis 
Mycoses 
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Clinical drug investigation 
Clinical Gastroenterology and Hepatology 
Clinical Infectious Diseases 
Clinical Journal of Pain 
Clinical Journal of the American Society of Nephrology 
Clinical Laboratory 
Clinical Medicine Insights: Therapeutics 
Clinical Microbiology and Infection 
Clinical Nephrology 
Clinical Neurology and Neurosurgery 
Clinical Neurophysiology 
Clinical Nutrition 
Clinical Oncology 
Clinical orthopaedics and related research 
Clinical Otolaryngology 
Clinical pediatrics 
Clinical Pharmacology and Therapeutics 
Clinical Rehabilitation 
Clinical Research in Cardiology 
CLINICAL RHEUMATOLOGY 
Clinical Therapeutics 
Clinical Transplantation 
Clinical Trials 
Clinics 
CNS Drugs 
Cochrane Database of Systematic Reviews 
Cocuk Enfeksiyon Dergisi 
Colorectal Disease 
Community Dental Health 
Community Dentistry and Oral Epidemiology 
Community Oncology 
Contact Dermatitis 
Contraception 
Crisis 
Critical Care Medicine 
Critical Pathways in Cardiology 
Current Alzheimer Research 
Current Medical Research and Opinion 
Current Oncology 
Danish Medical Journal 
DARU 
Das Gesundheitswesen 
Dementia and Geriatric Cognitive Disorders 
Dermatology 
Dermatology and therapy 
Diabetes and Vascular Disease Research 
Diabetes care 
Diabetes Research and Clinical Practice 
Diabetes Technology and Therapeutics 
Diabetes Therapy 
Diabetes, Obesity and Metabolism 
Diabetic Medicine 
Digestive and Liver Disease 
Digestive diseases and sciences 
Digestive Surgery 
Diseases of the Colon and Rectum 
DMW Deutsche Medizinische Wochenschrift 
Nan fang yi ke da xue xue bao = Journal of Southern 
Medical University 
National Medical Journal of China 
Nephrology Dialysis Transplantation 
Netherlands Journal of Medicine 
Neurologia 
Neurologia medico-chirurgica 
Neurologist 
Neurology 
Neuro-oncology 
Neurosurgery 
Neurourology and Urodynamics 
New Biotechnology 
NEW ENGLAND JOURNAL OF MEDICINE 
Nicotine and Tobacco Research 
North Carolina medical journal 
Nutrition and Diabetes 
OBESITY 
Obesity Research and Clinical Practice 
Obesity surgery 
Obstetrics and Gynecology 
Occupation and Health 
Occupational Medicine 
Ochsner journal 
Oncologist 
Oncology 
Open Respiratory Medicine Journal 
Open Rheumatology Journal 
Ophthalmic Epidemiology 
Ophthalmologica 
Ophthalmology 
Oral Oncology 
Orphanet journal of rare diseases 
Orthopedics 
Osteoarthritis and Cartilage 
Osteoporosis International 
Otolaryngology - Head and Neck Surgery 
Pacing and Clinical Electrophysiology 
Paediatric Anaesthesia 
Paediatrics and Child Health 
PAEDIATRICS AND INTERNATIONAL CHILD HEALTH 
Pain Medicine 
Pain physician 
Pain Practice 
Pan African Medical Journal 
PARASITES and VECTORS 
Payesh Health Monitor 
PEDIATRIC ALLERGY AND IMMUNOLOGY 
Pediatric Cardiology 
Pediatric Drugs 
PEDIATRIC EMERGENCY CARE 
Pediatric Infectious Disease Journal 
Pediatric obesity 
Pediatric Transplantation 
Pediatrics 
Pediatrics International 
Perioperative Medicine 
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Drug and Alcohol Dependence 
Drug Metabolism and Pharmacokinetics 
Drugs and Aging 
Ear and hearing 
ecancermedicalscience 
Eksperimental'naia i klinicheskaia gastroenterologiia = 
Experimental and clinical gastroenterology 
EMERGENCIAS 
Emergency Medicine Journal 
Emerging Infectious Diseases 
Endoscopy 
Enfermedades Infecciosas y Microbiologia Clinica 
Epidemiology and Infection 
Epidemiology and Psychiatric Science 
Epilepsia 
Epilepsy Research 
Europace 
European Annals of Otorhinolaryngology, Head and 
Neck Diseases 
European Child and Adolescent Psychiatry 
European Heart Journal 
EUROPEAN HEART JOURNAL-CARDIOVASCULAR 
IMAGING 
European Journal of Cancer 
European Journal of Cardio-Thoracic Surgery 
European Journal of Clinical Microbiology and 
Infectious Diseases 
European Journal of Clinical Nutrition 
European Journal of Gastroenterology and 
Hepatology 
European Journal of Haematology 
European Journal of Heart Failure 
European Journal of Hospital Pharmacy: Science and 
Practice 
European Journal of Human Genetics 
European Journal of Integrative Medicine 
European Journal of Neurology 
European Journal of Nuclear Medicine and Molecular 
Imaging 
EUROPEAN JOURNAL OF OBSTETRICS and 
GYNECOLOGY AND REPRODUCTIVE BIOLOGY 
European Journal of Obstetrics Gynecology and 
Reproductive Biology 
European Journal of Orthopaedic Surgery and 
Traumatology 
European Journal of Paediatric Neurology 
EUROPEAN JOURNAL OF PAIN 
European Journal of Preventive Cardiology 
European journal of public health 
European Journal of Radiology 
European Journal of Vascular and Endovascular 
Surgery 
European Neurology 
European Neuropsychopharmacology 
European Radiology 
European Respiratory Journal 
Peritoneal Dialysis International 
Personalized Medicine 
Pharmacogenetics and Genomics 
Pharmacogenomics 
Pharmacotherapy 
Pharmazie 
Physis: Revista de Saude Coletiva 
Plastic and reconstructive surgery 
PLOS MEDICINE 
PloS Neglected Tropical Diseases 
PM and R 
Polski Merkuriusz Lekarski 
Postepy Dermatologii I Alergologii 
Postgraduate medicine 
Practical Pharmacy and Clinical Remedies 
Prenatal Diagnosis 
Presse Medicale 
Preventing chronic disease 
PREVENTION SCIENCE 
Preventive Medicine 
Primary care diabetes 
Primary Care Respiratory Journal 
Proceedings of the National Academy of Sciences of 
the United States of America 
Progresos de Obstetricia y Ginecologia 
Progress in Modern Biomedicine 
Progress in Neuro-Psychopharmacology and 
Biological Psychiatry 
Prostate cancer and prostatic diseases 
Psychiatrische Praxis 
Psychological Medicine 
Psychologische Rundschau 
Psycho-Oncology 
Psychosomatics 
Psychotherapy Research 
Public health nutrition 
QJM 
QUALITY OF LIFE RESEARCH 
Radiol. bras 
Radiological Physics and Technology 
Radiology 
Rational Pharmacotherapy in Cardiology 
Rehabilitacion 
Renal Failure 
Reproductive biomedicine online 
Research in Autism Spectrum Disorders 
Research Journal of Pharmacy and Technology 
Respiratory medicine 
Reumatologia 
Reumatologia Clinica 
Revista Brasileira de Cardiologia Invasiva 
Revista Brasileira de Cirurgia Cardiovascular 
Revista Clinica de Medicina de Familia 
Revista clinica espanola 
Revista Colombiana de Cardiologia 
Revista Colombiana de Obstetricia y Ginecologia 
REVISTA DA ASSOCIACAO MEDICA BRASILEIRA 
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European Review for Medical and Pharmacological 
Sciences 
European Spine Journal 
European Urology 
Evaluation and Program Planning 
Evidence Based Medicine 
Experimental and Therapeutic Medicine 
Expert Review of Anticancer Therapy 
Familial Cancer 
Farmacia Hospitalaria 
Female pelvic medicine and reconstructive surgery 
Fertility and Sterility 
Fisioterapia 
Food and Nutrition Bulletin 
Foot and Ankle International 
Foot and Ankle Surgery 
Fortschritte auf dem Gebiete der Rontgenstrahlen 
und der Nuklearmedizin 
Forum of Clinical Oncology 
Frontiers in oncology 
Gastroenterologia y Hepatologia 
Gastroenterology 
Gastrointestinal Endoscopy 
Gazzetta Medica Italiana 
Genetics in Medicine 
Gerodontology 
Ginecologia y Obstetricia de Mexico 
GLOBAL HEALTH ACTION 
Global Journal of Health Science 
Global Public Health 
Gut 
Gut and Liver 
Gynecologic Endocrinology 
Gynecologic Oncology 
Haematologica 
Haemophilia 
Hawaii Journal of Medicine and Public Health 
Health 
Health Outcomes Research in Medicine 
Health promotion international 
Health Psychology 
Heart 
Heart Lung and Circulation 
Heart Rhythm 
Hellenic Journal of Cardiology 
Hematological Oncology 
Hematology/ Oncology and Stem Cell Therapy 
Hepatitis Monthly 
Hepato-Gastroenterology 
HEPATOLOGY 
Hepatology Research 
Hinyokika kiyo. Acta urologica Japonica 
HIP International 
HIV Clinical Trials 
HIV MEDICINE 
Hong Kong Medical Journal 
Hormone Research in Paediatrics 
Revista de Associacao Medica Brasileira 
Revista de enfermeria (Barcelona, Spain) 
Revista de la Sociedad Espanola del Dolor 
Revista de Salud Publica 
Revista de Saude Publica 
Revista espanola de anestesiologia y reanimacion 
Revista Espanola de Cardiologia 
Revista Espanola de Cirugia Ortopedica y 
Traumatologia 
Revista Espanola de Quimioterapia 
Revista Espanola de Salud Publica 
Revista Mexicana de Neurociencia 
Revista Panamericana de Salud Publica 
Revista Portuguesa de Cardiologia 
Revista Salud Publica (Bogota) 
Revue de Medecine Interne 
Revue de Neuropsychologie, Neurosciences 
Cognitives et Cliniques 
Revue des maladies respiratoires 
Revue du Rhumatisme (Edition Francaise) 
Rheumatology 
Rheumatology International 
Risk Analysis 
RUSSIAN JOURNAL OF CARDIOLOGY 
Salud Publica de Mexico 
Salud(i)Ciencia 
Sarcoma 
Saudi Medical Journal 
Scandinavian Cardiovascular Journal 
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES 
SCANDINAVIAN JOURNAL OF PUBLIC HEALTH 
Scandinavian Journal of Urology and Nephrology 
Scandinavian Journal of Work Environment and 
Health 
Schizophrenia Research 
Semergen 
Seminars in Spine Surgery 
Sex Education 
Sexual Health 
Sexually transmitted diseases 
Sexually Transmitted Infections 
Singapore Medical Journal 
Sleep 
South African Journal of Obstetrics and Gynaecology 
South African Medical Journal 
Spine 
Spine Deformity 
Spine Journal 
SpringerPlus 
STOCHASTIC ENVIRONMENTAL RESEARCH AND RISK 
ASSESSMENT 
Stroke 
Supportive Care in Cancer 
Surgery 
Surgical Endoscopy 
Surgical Endoscopy and Other Interventional 
Techniques 
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Hospital Practice 
HPB 
Human Reproduction 
Human Vaccines 
Human Vaccines and Immunotherapeutics 
Imaging in Medicine 
Indian Journal of Community Medicine 
Indian Journal of Dermatology 
Indian Journal of Medical and Paediatric Oncology 
Indian Journal of Pharmacology 
Indian journal of public health 
Infant, Child and Adolescent Nutrition 
Infection 
Infection Control and Hospital Epidemiology 
Infectious Diseases in Obstetrics and Gynecology 
Inflammatory Bowel Diseases 
Influenza and other Respiratory Viruses 
Injury 
Injury Prevention 
Insights into Imaging 
Intensive care medicine 
Internal medicine journal 
International Brazilian Journal of Urology 
International Forum of Allergy and Rhinology 
International Health 
International Journal for Quality in Health Care 
International journal of Alzheimer's disease 
International Journal of Antimicrobial Agents 
International Journal of Cancer 
International Journal of Cardiology 
International journal of chronic obstructive 
pulmonary disease 
International journal of clinical pharmacy 
International journal of clinical practice 
International Journal of COPD 
International Journal of Dermatology 
International Journal of Drug Development and 
Research 
International Journal of Eating Disorders 
International Journal of Environmental Research and 
Public Health 
International Journal of Geriatric Psychiatry 
International Journal of Group Psychotherapy 
International Journal of Gynecological Cancer 
International Journal of Gynecology and Obstetrics 
International Journal of Health Care Quality 
Assurance 
International journal of inflammation 
International Journal of Medical Engineering and 
Informatics 
International Journal of Nursing Studies 
International Journal of Obesity 
International journal of pediatric otorhinolaryngology 
International Journal of Pharmaceutical Sciences 
Review and Research 
International Journal of Pharmacology 
Surgical Laparoscopy, Endoscopy and Percutaneous 
Techniques 
Swiss Medical Weekly 
Technology in Cancer Research and Treatment 
Telemedicine and e-Health 
Theoretical biology and medical modelling 
Therapeutic Advances in Psychopharmacology 
Thorax 
Thrombosis and Haemostasis 
Thrombosis Journal 
Thrombosis Research 
Tijdschrift voor Geneeskunde 
Tobacco Control 
Toxicon 
Toxins 
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL 
MEDICINE AND HYGIENE 
Transfusion 
Transfusion and Apheresis Science 
TRANSPLANT INTERNATIONAL 
Transplantation 
Transplantation Proceedings 
Trials 
Tropical Medicine and International Health 
Tumor 
Turkderm Deri Hastaliklari ve Frengi Arsivi 
TURKISH JOURNAL OF MEDICAL SCIENCES 
Ultrasound in Obstetrics and Gynecology 
University of Toronto Medical Journal 
Vaccine 
Vakcinologie 
Vascular and endovascular surgery 
Vector-Borne and Zoonotic Diseases 
Vestnik Dermatologii i Venerologii 
Vojnosanitetski pregled. Military-medical and 
pharmaceutical review 
Voprosy Onkologii 
Vox sanguinis 
Wiener Klinische Wochenschrift 
Wiener Medizinische Wochenschrift 
Work 
World Chinese Journal of Digestology 
World Journal of Emergency Surgery 
World Journal of Gastroenterology 
World journal of surgery 
World Journal of Surgical Oncology 
World Neurosurgery 
Wounds 
ZDRAVSTVENO VARSTVO 
Zeitschrift fur Evidenz Fortbildung und Qualitat im 
Gesundheitswesen  
Zeitschrift fur Gerontologie und Geriatrie 
Zhongguo Shiyong Neike Zazhi / Chinese Journal of 
Practical Internal Medicine 
Zhongguo Xinyao yu Linchuang Zazhi 
Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi 
jiehe zazhi = Chinese journal of integrated 
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International Journal of Pharmacy and 
Pharmaceutical Sciences 
International Journal of Preventive Medicine 
International Journal of Radiation Oncology, Biology, 
Physics 
International Journal of Spine Surgery 
International Journal of Stroke 
International Journal of Tuberculosis and Lung 
Disease 
International Journal of Urology 
International Journal of Vascular Medicine 
International Orthopaedics 
INTERNATIONAL UROGYNECOLOGY JOURNAL 
International Wound Journal 
IOVS 
traditional and Western medicine / Zhongguo 
Zhong xi yi jie he xue hui, Zhongguo Zhong yi yan jiu 
yuan zhu ban 
Zhongguo Zhong yao za zhi = Zhongguo zhongyao 
zazhi = China journal of Chinese materia medica 
Zhonghua lao dong wei sheng zhi ye bing za zhi = 
Zhonghua laodong weisheng zhiyebing zazhi = 
Chinese journal of industrial hygiene and 
occupational diseases 
Zhonghua liu xing bing xue za zhi = Zhonghua 
liuxingbingxue zazhi 
Zhonghua wei chang wai ke za zhi = Chinese journal 
of gastrointestinal surgery 
Zhonghua yu fang yi xue za zhi [Chinese journal of 
preventive medicine] 
Zhonghua zhong liu za zhi [Chinese journal of 
oncology] 
Other 
American Water Works Association Journal 
Child Abuse and Neglect 
Disasters 
Environment International 
European Journal of Operational Research  
Journal of interpersonal violence 
Journal of Water and Health 
MATHEMATICAL MODELLING OF NATURAL 
PHENOMENA 
PLoS One 
Traffic Injury Prevention 
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Appendix 7 Search terms to classify cost-utility and cost-benefit analyses 
The following search terms were used to classify articles within our final database of full health economic 
evaluations according to study type. Searches were conducted in titles and abstracts. Search terms could 
classify an article as a cost-utility analysis, cost-benefit analysis, both, or neither. Articles in our database which 
did not contain search terms for cost-utility analyses or cost-benefit analyses were categorized as cost-
effectiveness analyses. Question marks (“?”) represent a single wildcard character or space.   
Type of analysis Search terms implemented in Excel database 
Cost-utility analysis Cost?utility 
[Additionally, all results of DALY and QALY 
searches also included] 
CUA employing DALYs DALY, Disability?adjusted?life?year 
CUA employing QALYs QALY, Quality?adjusted?life?year, EQ?5D, 
SF?36, SF?12, SF?6D 
Cost-benefit analysis Cost?benefit, benefit?cost, net?benefit, 
net?monetary?benefit 
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Appendix 8 Search findings by database – all articles and databases 
All searches were conducted on 3 May 2014, except for the LILACS database, which was searched on 12 May 2014. The first database listed identified the largest number of 
economic evaluations. Remaining databases are listed in order of those which identified the most additional economic evaluations beyond those already identified by other 
databases higher on the list.  
Database Number of 
records 
identified by 
search 
Number of 
economic 
evaluations 
meeting inclusion 
criteria 
Sensitivity 
(% of total economic 
evaluations) 
Specificity 
(% of search results 
classified as  
economic evaluations) 
Additional 
economic 
evaluations   
(Beyond those 
found in databases 
higher on this list) 
Cumulative 
% 
Scopus  9006 2409 85% 27% 2409 85% 
NHS EED 3634 2280 80% 63% 314 96% 
Medline 7566 2254 79% 30% 65 98% 
Global 
Health 2219 691 24% 31% 19 99% 
Wiley 
HEED 2175 1707 60% 78% 13 99% 
Web of 
Science 8738 1852 65% 21% 6 99% 
Biosis 2643 834 29% 32% 5 100% 
Embase 7558 2217 78% 29% 4 100% 
Cinahl 2580 1097 39% 43% 4 100% 
Scielo 162 53 2% 33% 3 100% 
PsycInfo 808 183 6% 23% 1 100% 
EconLit 186 42 1% 23% 1 100% 
Lilacs 132 42 1% 32% 0 100% 
TOTAL 47,407 2844         
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Appendix 9 Search findings by database – excluding NHS EED and Wiley HEED 
All searches were conducted on 3 May 2014, except for the LILACS database, which was searched on 12 May 2014. The first database listed identified the largest number of 
economic evaluations. Remaining databases are listed in order of those which identified the most additional economic evaluations beyond those already identified by other 
databases higher on the list. As NHS EED ceased to update records from March 2015 and Wiley HEED ceased to be available from the end of 2014, they have been placed at 
the bottom of the list to permit examination of available databases.  
Database Number of 
records 
identified by 
search 
Number of 
economic 
evaluations 
meeting inclusion 
criteria 
Sensitivity 
(% of total economic 
evaluations) 
Specificity 
(% of search results 
classified as  
economic evaluations) 
Additional 
economic 
evaluations   
(Beyond those 
found in databases 
higher on this list) 
Cumulative 
% 
Scopus  9006 2409 85% 27% 2409 85% 
Medline 7566 2254 79% 30% 156 90% 
Global 
Health 2219 691 24% 31% 35 91% 
Web of 
Science 8738 1852 65% 21% 22 92% 
Embase 7558 2217 78% 29% 14 93% 
Biosis 2643 834 29% 32% 7 92% 
Cinahl 2580 1097 39% 43% 5 93% 
Scielo 162 53 2% 33% 3 93% 
EconLit 186 42 1% 23% 1 93% 
PsycInfo 808 183 6% 23% 1 93% 
Lilacs 132 42 1% 32% 0 93% 
(NHS EED) (3634) (2280) (80%) (63%) (183) (100%) 
(Wiley HEED) (2175) (1707) (60%) (78%) (8) (100%) 
TOTAL 41,598 2653         
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Appendix 10 Search findings by database – only articles studying low- and middle-income countries, excluding NHS EED and Wiley HEED 
All searches were conducted on 3 May 2014, except for the LILACS database, which was searched on 12 May 2014. The first database listed identified the largest number of 
economic evaluations. Remaining databases are listed in order of those which identified the most additional economic evaluations beyond those already identified by other 
databases higher on the list. L&MIC: Low- and middle-income country. As NHS EED ceased to update records from March 2015 and Wiley HEED ceased to be available from 
the end of 2014, they have been placed at the bottom of the list to permit examination of available databases. 
Database Number of 
records 
identified by 
search 
Number of L&MIC 
economic 
evaluations 
meeting inclusion 
criteria  
Sensitivity 
(% of total L&MIC 
economic evaluations) 
Specificity 
(% of search results 
classified as L&MIC 
economic evaluations) 
Additional L&MIC 
economic 
evaluations   
(Beyond those 
found in databases 
higher on this list) 
Cumulative 
% 
Scopus 9006 428 81% 5% 428 81% 
Medline 7566 380 72% 5% 40 89% 
Global 
Health  2219 287 54% 13% 23 93% 
Biosis  2643 181 34% 7% 4 94% 
Embase 7558 403 76% 5% 4 95% 
Web of 
Science 8738 316 60% 4% 3 95% 
Cinahl 2580 119 23% 5% 1 95% 
Scielo 162 43 8% 27% 1 96% 
Lilacs  132 39 7% 30% 0 96% 
PsycInfo 808 21 4% 3% 0 96% 
EconLit 186 6 1% 3% 0 96% 
(NHS EED)  (3634) (378) (72%) (10%) (21) (100%) 
(Wiley HEED) (2175) (294) (56%) (14%) (2) (100%) 
TOTAL 41,598 504         
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Appendix 11 Journal concentration by income group of countries studied 
 
 LICs Lower-MICs Upper-MICs HICs All 
Total articles 104 121 391 2350 2844 
Avg articles per 
journal 
2.4 2.0 1.7 2.9 2.9 
Total journals 44 61 226 802 967 
% articles in top 
10 journals 
62% 52% 27% 22% 21% 
Total articles in 
top 10 journals 
64 63 105 509 600 
% articles in top 
20 journals 
77% 66% 38% 29% 29% 
Total articles in 
top 20 journals 
80 80 147 684 813 
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Appendix 12 Number and proportion of economic evaluations by type and income group 
In this table, “cost-effectiveness analyses” refers to articles meeting our definition of a full economic evaluation but not containing any keywords to define it more 
specifically as a cost-utility or cost-benefit analysis. Articles can be classified as both cost-utility and cost-benefit analyses if they contain keywords for both. DALY: 
disability-adjusted life year, QALY: quality-adjusted life-year. 
 
 Income group studied  
 LICs  Lower-
MICs 
 Upper-
MICs 
 HICs  Multiple 
income groups 
 Total  
Type of analysis N % N % N % N % N % N % 
Cost-utility 
analysis (only) 51 49% 63 52% 172 44% 1391 59% 39 61.9% 1605 56% 
DALY 44 42% 40 33% 49 13% 34 1% 28 44.4% 112 4% 
QALY 7 7% 22 18% 120 31% 1332 57% 10 15.9% 1465 52% 
Cost-benefit 
analysis (only) 5 5% 3 2% 13 3% 60 3% 1 1.6% 79 3% 
Cost-benefit & 
cost-utility 
analysis 1 1.0% 3 2.5% 10 2.6% 57 2.4% 1 1.6% 68 2% 
Cost-
effectiveness 
analysis  47 45% 52 43% 196 50% 842 36% 22 34.9% 1092 38% 
Total 104 100% 121 100% 391 100% 2350 100% 63 100.0% 2844 100% 
% 3.7%  4.3%  13.7%  82.6%  2.2%  100.0%  
 
 
 
 
 
 
